|Veröffentlichungsdatum||14. Juni 2011|
|Eingetragen||30. Mai 2006|
|Prioritätsdatum||30. Mai 2006|
|Auch veröffentlicht unter||EP2032070A2, US8192665, US8309114, US8377356, US8512735, US8613877, US8999369, US20070278720, US20070282431, US20110060073, US20110207843, US20120228810, US20130041065, US20130134620, US20130324636, US20140121294, WO2007142752A2, WO2007142752A3|
|Veröffentlichungsnummer||11443870, 443870, US 7959940 B2, US 7959940B2, US-B2-7959940, US7959940 B2, US7959940B2|
|Erfinder||David C. Gale, Yunbing Wang, Syed Faiyaz Ahmed Hossainy, Bin Huang, Garth L. Wilkes, Vincent J. Gueriguian|
|Ursprünglich Bevollmächtigter||Advanced Cardiovascular Systems, Inc.|
|Zitat exportieren||BiBTeX, EndNote, RefMan|
|Patentzitate (347), Nichtpatentzitate (49), Referenziert von (7), Klassifizierungen (22), Juristische Ereignisse (2)|
|Externe Links: USPTO, USPTO-Zuordnung, Espacenet|
1. Field of the Invention
This invention relates to implantable medical devices and methods of fabricating implantable medical devices.
2. Description of the State of the Art
This invention relates to radially expandable endoprostheses, which are adapted to be implanted in a bodily lumen. An “endoprosthesis” corresponds to an artificial device that is placed inside the body. A “lumen” refers to a cavity of a tubular organ such as a blood vessel.
A stent is an example of such an endoprosthesis. Stents are generally cylindrically shaped devices, which function to hold open and sometimes expand a segment of a blood vessel or other anatomical lumen such as urinary tracts and bile ducts. Stents are often used in the treatment of atherosclerotic stenosis in blood vessels. “Stenosis” refers to a narrowing or constriction of the diameter of a bodily passage or orifice. In such treatments, stents reinforce body vessels and prevent restenosis following angioplasty in the vascular system. “Restenosis” refers to the reoccurrence of stenosis in a blood vessel or heart valve after it has been treated (as by balloon angioplasty, stenting, or valvuloplasty) with apparent success.
The treatment of a diseased site or lesion with a stent involves both delivery and deployment of the stent. “Delivery” refers to introducing and transporting the stent through a bodily lumen to a region, such as a lesion, in a vessel that requires treatment. “Deployment” corresponds to the expanding of the stent within the lumen at the treatment region. Delivery and deployment of a stent are accomplished by positioning the stent about one end of a catheter, inserting the end of the catheter through the skin into a bodily lumen, advancing the catheter in the bodily lumen to a desired treatment location, expanding the stent at the treatment location, and removing the catheter from the lumen.
In the case of a balloon expandable stent, the stent is mounted about a balloon disposed on the catheter. Mounting the stent typically involves compressing or crimping the stent onto the balloon. The stent is then expanded by inflating the balloon. The balloon may then be deflated and the catheter withdrawn. In the case of a self-expanding stent, the stent may be secured to the catheter via a constraining member such as a retractable sheath or a sock. When the stent is in a desired bodily location, the sheath may be withdrawn which allows the stent to self-expand.
The stent must be able to satisfy a number of mechanical requirements. First, the stent must be capable of withstanding the structural loads, namely radial compressive forces, imposed on the stent as it supports the walls of a vessel. Therefore, a stent must possess adequate radial strength. Radial strength, which is the ability of a stent to resist radial compressive forces, is due to strength and rigidity around a circumferential direction of the stent. Radial strength and rigidity, therefore, may also be described as, hoop or circumferential strength and rigidity.
Once expanded, the stent must adequately maintain its size and shape throughout its service life despite the various forces that may come to bear on it, including the cyclic loading induced by the beating heart. For example, a radially directed force may tend to cause a stent to recoil inward. Generally, it is desirable to minimize recoil. In addition, the stent must possess sufficient flexibility to allow for crimping, expansion, and cyclic loading. Longitudinal flexibility is important to allow the stent to be maneuvered through a tortuous vascular path and to enable it to conform to a deployment site that may not be linear or may be subject to flexure. Finally, the stent must be biocompatible so as not to trigger any adverse vascular responses.
The structure of a stent is typically composed of scaffolding that includes a pattern or network of interconnecting structural elements often referred to in the art as struts or bar arms. The scaffolding can be formed from wires, tubes, or sheets of material rolled into a cylindrical shape. The scaffolding is designed so that the stent can be radially compressed (to allow crimping) and radially expanded (to allow deployment). A conventional stent is allowed to expand and contract through movement of individual structural elements of a pattern with respect to each other.
Additionally, a medicated stent may be fabricated by coating the surface of either a metallic or polymeric scaffolding with a polymeric carrier that includes an active or bioactive agent or drug. Polymeric scaffolding may also serve as a carrier of an active agent or drug.
Furthermore, it may be desirable for a stent to be biodegradable. In many treatment applications, the presence of a stent in a body may be necessary for a limited period of time until its intended function of, for example, maintaining vascular patency and/or drug delivery is accomplished. Therefore, stents fabricated from biodegradable, bioabsorbable, and/or bioerodable materials such as bioabsorbable polymers should be configured to completely erode only after the clinical need for them has ended.
A potential problem with polymeric stents is that their struts or bar arms can crack during crimping and expansion. This is especially the case with brittle polymers. The localized portions of the stent pattern subjected to substantial deformation during crimping and expansion tend to be the most vulnerable to failure.
Therefore, it is desirable for a stent to have flexibility and resistance to cracking during deployment. It is also advantageous for a stent to be rigid and resistant to creep after deployment. It would also be desirable to be able to control the degradation rate of the device.
Certain embodiments of the invention include a stent comprising a structural element including a bioceramic/polymer composite, the composite having plurality of bioceramic particles dispersed within a polymer.
Further embodiments of the invention include a method for fabricating an implantable medical device comprising forming a suspension solution including a fluid, a polymer and bioceramic particles, wherein the polymer is dissolved in the fluid, and wherein the bioceramic particles are dispersed in the solution. The method may further include combining the suspension solution with a second fluid, wherein the second fluid is a poor solvent for the polymer and allowing at least some of polymer to precipitate upon combining the suspension solution with the second fluid, wherein at least some of the bioceramic particles precipitate with the precipitated polymer to form a composite mixture. The method may also include fabricating an implantable medical device from the composite mixture.
Additional embodiments of the invention include a method for fabricating an implantable medical device comprising forming a suspension solution including a fluid, a polymer and bioceramic particles, wherein the polymer is dissolved in the fluid, and wherein the bioceramic particles are dispersed in the solution and combining the suspension solution with a second fluid, wherein the second fluid is a poor solvent for the polymer and allowing at least some of polymer to precipitate upon combining the suspension solution with the second fluid, wherein at least some of the bioceramic particles precipitate with the precipitated polymer to form a composite mixture. The composite mixture may be mixed with a second polymer to form a second composite mixture, the bioceramic particles being dispersed within the second composite mixture by the mixing. The method may further include fabricating a medical device from the second composite mixture.
Other embodiments of the invention include a method of fabricating an implantable medical device comprising treating the surface of a plurality of bioceramic particles with an adhesion promoter and forming a composite including the bioceramic particles dispersed within a polymer, the adhesion promoter enhancing bonding between the polymer and the bioceramic particles. The method may also include fabricating an implantable medical device from the composite.
Additional embodiments of the invention include a method for fabricating an implantable medical device comprising combining a plurality of bioceramic particles and a semicrystalline polymer to form a bioceramic polymer composite, the bioceramic particles being dispersed with the polymer. The method may also include allowing crystallites to form adjacent to or around the bioceramic particles during formation of the composite, the crystallites being dispersed throughout an amorphous domain of the composite and fabricating an implantable medical device from the composite.
Certain other embodiments of the invention include a method for controlling a degradation rate in an implantable medical device comprising selecting bioceramic particles having degradation products in physiological conditions that can modify a degradation rate of a biodegradable polymer and combining a plurality of bioceramic particles and a biodegradable polymer to form a composite, wherein the bioceramic particles are dispersed within the biodegradable polymer. The method further may further include fabricating an implantable medical device from the composite.
Those of ordinary skill in the art will realize that the following description is of the invention is illustrative only and not in any way limiting. Other embodiments of the invention will readily suggest themselves to such skilled persons based on the disclosure herein. All such embodiments are within the scope of this invention.
For the purposes of the present invention, the following terms and definitions apply:
The “glass transition temperature,” Tg, is the temperature at which the amorphous domains of a polymer change from a brittle vitreous state to a solid deformable or ductile state at atmospheric pressure. In other words, the Tg corresponds to the temperature where the onset of segmental motion in the chains of the polymer occurs. When an amorphous or semicrystalline polymer is exposed to an increasing temperature; the coefficient of expansion and the heat capacity of the polymer both increase as the temperature is raised, indicating increased molecular motion. As the temperature is raised the actual molecular volume in the sample remains constant, and so a higher coefficient of expansion points to an increase in free volume associated with the system and therefore increased freedom for the molecules to move. The increasing heat capacity corresponds to an increase in heat dissipation through movement. Tg of a given polymer can be dependent on the heating rate and can be influenced by the thermal history of the polymer. Furthermore, the chemical structure of the polymer heavily influences the glass transition by affecting mobility.
“Stress” refers to force per unit area, as in the force acting through a small area within a plane. Stress can be divided into components, normal and parallel to the plane, called normal stress and shear stress, respectively. True stress denotes the stress where force and area are measured at the same time. Conventional stress, as applied to tension and compression tests, is force divided by the original gauge length.
“Strength” refers to the maximum stress along an axis which a material will withstand prior to fracture. The ultimate strength is calculated from the maximum load applied during the test divided by the original cross-sectional area.
“Modulus” may be defined as the ratio of a component of stress or force per unit area applied to a material divided by the strain along an axis of applied force that results from the applied force. For example, a material has both a tensile and a compressive modulus. A material with a relatively high modulus tends to be stiff or rigid. Conversely, a material with a relatively low modulus tends to be flexible. The modulus of a material depends on the molecular composition and structure, temperature of the material, amount of deformation, and the strain rate or rate of deformation. For example, below its Tg, a polymer tends to be brittle with a high modulus. As the temperature of a polymer is increased from below to above its Tg, its modulus decreases.
“Strain” refers to the amount of elongation or compression that occurs in a material at a given stress or load.
“Elongation” may be defined as the increase in length in a material which occurs when subjected to stress. It is typically expressed as a percentage of the original length.
“Toughness” is the amount of energy absorbed prior to fracture, or equivalently, the amount of work required to fracture a material. One measure of toughness is the area under a stress-strain curve from zero strain to the strain at fracture. Thus, a brittle material tends to have a relatively low toughness.
“Solvent” is defined as a substance capable of dissolving or dispersing one or more other substances or capable of at least partially dissolving or dispersing the substance(s) to form a uniformly dispersed solution at the molecular- or ionic-size level. The solvent should be capable of dissolving at least 0.1 mg of the polymer in 1 ml of the solvent, and more narrowly 0.5 mg in 1 ml at ambient temperature and ambient pressure.
As used herein, an “implantable medical device” includes, but is not limited to, self-expandable stents, balloon-expandable stents, stent-grafts, implantable cardiac pacemakers and defibrillators; leads and electrodes for the preceding; implantable organ stimulators such as nerve, bladder, sphincter and diaphragm stimulators, cochlear implants; prostheses, vascular grafts, grafts, artificial heart valves and cerebrospinal fluid shunts.
An implantable medical device can be designed for the localized delivery of a therapeutic agent. A medicated implantable medical device may be constructed by coating the device with a coating material containing a therapeutic agent. The substrate of the device may also contain a therapeutic agent.
The geometry or shape of an implantable medical device may vary throughout its structure to allow radial expansion and compression. A pattern may include portions of structural elements or struts that are straight or relatively straight, an example being a portion 120. In addition, patterns may include structural elements or struts that include curved or bent portions such as portions 130, 140, and 150.
An implantable medical device can also be made partially or completely from a biodegradable, bioabsorbable, or biostable polymer. A polymer for use in fabricating an implantable medical device can be biostable, bioabsorbable, biodegradable or bioerodable. Biostable refers to polymers that are not biodegradable. The terms biodegradable, bioabsorbable, and bioerodable are used interchangeably and refer to polymers that are capable of being completely degraded and/or eroded when exposed to bodily fluids such as blood and can be gradually resorbed, absorbed, and/or eliminated by the body. The processes of breaking down and absorption of the polymer can be caused by, for example, hydrolysis and metabolic processes.
However, polymers tend to have a number of shortcomings for use as materials for implantable medical devices such as stents. Many biodegradable polymers have a relatively low modulus at the physiological conditions in the human body. In general, compared to metals, the strength to weight ratio of polymers is smaller than that of metals. A polymeric stent with inadequete radial strength can result in mechanical failure or recoil inward after implantation into a vessel. To compensate for the relatively low modulus, a polymeric stent requires significantly thicker struts than a metallic stent, which results in an undesirably large profile.
Another shortcoming of polymers is that many polymers, such as biodegradable polymers, tend to be brittle under physiological conditions or conditions within a human body. Specifically, such polymers can have a Tg above human body temperature which is approximately 37° C. These polymer systems exhibit a brittle fracture mechanism in which there is little or no plastic deformation prior to failure. As a result, a stent fabricated from such polymers can have insufficient toughness for the range of use of a stent.
Other potential problems with polymeric stents include creep, stress relaxation, and physical aging. Creep refers to the gradual deformation that occurs in a polymeric contruct subjected to an applied load. Creep occurs even when the applied load is constant.
It is believed that the delayed response of polymer chains to stress during deformation causes creep behavior. As a polymer is deformed, polymeric chains in an initial state rearrange to adopt a new equilibrium configuration. Rearrangement of chains takes place slowly with the chains retracting by folding back to their initial state. For example, an expanded stent can retract radially inward, reducing the effectiveness of a stent in maintaining desired vascular patency. The rate at which polymers creep depends not only on the load, but also on temperature. In general, a loaded construct creeps faster at higher temperatures.
Stress relaxation is also a consequence of delayed molecular motions as in creep. Contrary to creep, however, which is experienced when the load is constant, stress relaxation occurs when deformation (or strain) is constant and is manifested by a reduction in the force (stress) required to maintain a constant deformation.
Physical aging, as used herein, refers to densification in the amorphous regions of a semi-crystalline polymer. Densification is the increase in density of a material or region of a material. Densification, and thus physical aging, is also the result of relaxation or rearrangement of polymer chains.
Various embodiments of the present invention include an implantable medical device fabricated from a composite including a polymer matrix or continuous phase and bioceramic particles as a discrete phase. The bioceramic particles may tend to reduce or eliminate a number of the above-mentioned shortcomings of polymers. For example, the bioceramic particles can increase the toughness and modulus and modify the degradation rate of the polymer. In some embodiments, the composite may include a plurality of bioceramic particles dispersed within the polymer.
In general, it is desirable for the bioceramic particles to be uniformly dispersed throughout the biodegradable polymer. The more uniform the dispersion of the particles results in more uniform properties of the composite and a device fabricated from the composite. For example, a uniform dispersion can result in a uniform increase in toughness and modulus and modification of degradation rate. In some embodiments, the bioceramic particles are uniformly or substantially uniformly dispersed within the biodegradable polymer.
In certain embodiments, a structural element of an implantable medical device may be fabricated from a bioceramic/polymer composite. Structural elements can include, but are not limited to, any supporting element such as a strut, wire, or filament.
Bioceramics can include any ceramic material that is compatible with the human body. More generally, bioceramic materials can include any type of compatible inorganic material or inorganic/organic hybrid material. Bioceramic materials can include, but are not limited to, alumina, zirconia, apatites, calcium phosphates, silica based glasses, or glass ceramics, and pyrolytic carbons. Bioceramic materials can be bioabsorbable and/or active. A bioceramic is active if it actively takes part in physiological processes. A bioceramic material can also be “inert,” meaning that the material does not absorb or degrade under physiological conditions of the human body and does not actively take part in physiological processes.
Illustrative examples of apatites and other calcium phosphates, include, but are not limited hydroxyapatite (Ca10(PO4)6(OH)2), floroapatite (Ca10(PO4)6F2), carbonate apatide (Ca10(PO4)6CO3), tricalcium phosphate (Ca3(PO4)2), octacalcium phosphate (Ca8H2(PO4)6-5H2O), octacalcium phosphate (Ca8H2(PO4)6-5H2O), calcium pyrophosphate (Ca2P2O7-2H2O), tetracalcium phosphate (Ca4P2O9), and dicalcium phosphate dehydrate (CaHPO4-2H2O).
The term bioceramics can also include bioactive glasses that are bioactive glass ceramics composed of compounds such as SiO2, Na2O, CaO, and P2O5. For example, a commercially available bioactive glass, Bioglass®, is derived from certain compositions of SiO2—Na2O—K2O—CaO—MgO—P2O5 systems. Some commercially available bioactive glasses include, but are not limited to:
45S5: 46.1 mol % SiO2, 26.9 mol % CaO, 24.4 mol % Na2O and 2.5 mol % P2O5;
58S: 60 mol % SiO2, 36 mol % CaO, and 4 mol % P2O5; and
S70C30: 70 mol % SiO2, 30 mol % CaO.
Another commercially available glass ceramic is A/W.
In some embodiments, bioceramic particles in a composite implantable medical device may be used to inhibit or prevent infection since some bioceramics can have an anti-infective property. Bioceramics may release various ions such as calcium and phosphate ions which broadly exist in human body fluid and blood plasma. Examples of bioceramics that release calcium and/or phosphate ions include various calcium phosphates and bioactive glasses. The released ions may depress foreign body reaction. Trends Biomater. Artif. Tren, Vol 18 (1), pp 9-17.
As indicated above, an implantable medical device such as a stent can be medicated by incorporating an active agent in a coating over the device or within the substrate of the device. In some embodiments, the ions released from bioceramics can have an additive therapeutic and/or a synergistic therapeutic effect to the active agent. For example, ions can be used in conjunction with anti-proliferative and/or anti-inflammatory agents.
Bioceramic particles can be partially or completely made from a biodegradable, bioabsorbable, or biostable ceramic. Examples of bioabsorbable bioceramics include various types of bioglass materials, tetracalcium phosphate, amorphous calcium phosphate, alpha-tricalcium phosphate, and beta-tricalcium phosphate. Biostable bioceramics include alumina and zirconia.
Various sizes of the bioceramic particles may be used in the composite. For example, the bioceramic particles can include, but are not limited to, nanoparticles and/or micro particles. A nanoparticle refers to a particle with a characteristic length (e.g., diameter) in the range of about 1 nm to about 1,000 nm. A micro particle refers to a particle with a characteristic length in the range of greater than 1,000 nm and less than about 10 micrometers. Additionally, bioceramic particles can be of various shapes, including but not limited to, spheres and fibers.
Additionally, the particles size distribution can be important in modifying the properties of the polymer. Generally, a narrow size distribution is preferable.
The composite of a structural element of a device may have between 0.01% and 10% of bioceramic particles by weight, or more narrowly, between 0.5% and 2% bioceramic particles by weight as compared to the polymer matrix of the composite.
As indicated above, the bioceramic particles can reduce or eliminate a number of shortcomings of polymers that are used for implantable medical devices. In one aspect of the invention, bioceramic particles can increase the fracture toughness of polymers of implantable medical device. In general, the higher the fracture toughness, the more resistant a material is to the propagation of cracks. In some embodiments, bioceramic particles may be used in a composite having a matrix polymer that is brittle at physiological conditions. In particular, such a polymer can have a Tg above body temperature. In one embodiment, the bioceramic particles may be nanoparticles.
Certain regions of an implantable medical device, such as a stent, experience a high degree of stress and strain when the device is under stress during use. For example, when a stent is crimped and deployed, curved or bending regions such as portions 130, 140, and 150 can have highly concentrated strain which can lead to fracture. The bioceramic particles can increase fracture toughness by reducing the concentration of strain by dispersing the strain over a large volume of the material. Particles can absorb energy due to applied stress and disperse energy about a larger volume in the bioceramic/polymer composite.
Therefore, rather than being highly concentrated the stress and strain in a device fabricated from a bioceramic composite is divided into many small interactions involving numerous individual particles. When a crack is initiated in the material and starts traveling through the composite, the crack breaks up into finer and finer cracks due to interaction with the particles. Thus, the particles tend to dissipate the energy of imparted to the device by the applied stress. In general, the increase in the toughness is directly proportional to the size of the particles. For a give weight ratio of particles to matrix, as the size of the particles decreases the number of particles dispersed throughout the device per unit volume also increases. Thus, the number of particles to disperse the energy of applied stress to the device increases. Therefore, it is advantageous to use nanoparticles to increase the toughness of the polymer. It has been shown that the fracture toughness of a polymeric material can be improved by using nanoparticles as a discrete or reinforcing phase in a composite. J. of Applied Polymer Science, 94 (2004) 796-802.
Bioceramic particles, more particularly nano-bioceramic particles, by providing more crystallites in a network in the bioceramic/polymer composite increase fracture toughness.
In yet another aspect of the invention, bioceramic particles can be used to increase the modulus of the polymer. As indicated above, a polymeric stent requires a high radial strength in order to provide effective scaffolding of a vessel. Many biodegradable polymers have a relatively low modulus as compared to metals. A composite with bioceramic particles with a higher modulus than a matrix polymer may have a higher modulus than the polymer. The higher modulus may allow for the manufacture of a composite stent with much thinner struts than a stent fabricated from the matrix polymer alone. Examples of relatively low modulus polymers include, but are not limited to, poly(D,L-lactide-co-glycolide), poly(lactide-co-caprolactone), poly(lactide-co-trimethylene carbonate), poly(glycolide-co-caprolactone), and poly(D,L-lactide). It has been reported that composites with nanoparticles can increase the modulus of a polymer by 1-2 orders of magnitude. Mechanical Properties of Polymers and Composites, Lawrence E. Nielsen and Robert F. Landel, 2nd ed., p. 384-385 (1993).
In addition, bioceramic particles in a polymer composite can also reduce or eliminate creep, stress relaxation, and physical aging. It is believed that particles can act as “net point” that reduce or inhibit movement of polymer chains in amorphous regions of a polymer.
Additionally, in composites fabricated from semicrystalline polymers, the crystallinity of a bioceramic/polymer composite that forms an implantable device can be controlled to reduce or eliminate creep, stress relaxation, and physical aging. As indicated above, these phenomena in a polymer are due to rearrangement or relaxation of polymer chains.
In general, as the crystallinity of a semicrystalline polymer increases, physical aging creep, and stress relaxation are reduced. This is likely due to the fact that polymer chains in the amorphous domains capable of movement are reduced by the crystalline domains. However, increasing crystallinity can result in brittleness in a polymer at physiological conditions.
In further embodiments, a structural element of an implantable medical device may include a composite having a plurality of crystalline domains dispersed within an amorphous biodegradable polymeric matrix phase. The crystalline domains may be formed around bioceramic particles. In certain embodiments, the composite that makes up the structural element may have a relatively low crystallinity. For example, the crystallinity can be less than 50%, 30%, 20%, or less than 10%.
Additionally, the device can be fabricated so that the resulting composite has a relatively large number of crystalline domains that are relatively small. In certain embodiments, the average crystal size can be less than 10 microns, 5 microns, or less than 2 microns. As the size of the crystalline domains decreases along with an increase in the number of domains, the polymer may become less brittle and, which increases the fracture toughness. Although the crystallinity of the resulting polymer can be relatively low, the presence of the relatively large number of relatively small crystalline domains can reduce or eliminate physical aging, creep, and stress relaxation.
The size and number of crystallites domains can be controlled during formation of a polymer construct from an implantable medical device is fabricated. Polymer constructs, such as tubes, can be formed using various types of forming methods, including, but not limited to extrusion or injection molding. Representative examples of extruders include, but are not limited to, single screw extruders, intermeshing co-rotating and counter-rotating twin-screw extruders, and other multiple screw masticating extruders.
In some embodiments, a mixture of a polymer and bioceramic particles can be extruded to form a polymer construct, such as a tube. A polymer melt mixed with the bioceramic particles can be conveyed through an extruder and forced through a die in the shape of as an annular film in the shape of a tube. The annular film can be cooled below the melting point, Tm, of the polymer to form an extruded polymeric tube. For example, the annular film may be conveyed through a water bath at a selected temperature. Alternatively, the annular film may be cooled by a gas at a selected temperature. The annular film may be cooled at or near an ambient temperature, e.g. 25° C. Alternatively, the annular film may be cooled at a temperature below ambient temperature.
In general, crystallization in a polymer tends to occur in a polymer at temperatures between Tg and Tm of the polymer. Therefore, in some embodiments, the temperature of the polymer construct during cooling can be between Tg and Tm. As the temperature of the extruded mixture is cooled below Tm to form a polymer construct, such as a tube, the bioceramic particles provide a point of nucleation in the polymer melt for the formation of crystalline domains.
A network of many small crystalline domains is formed, which can work to tie crystalline domains together and reduce, inhibit or prevent fracturing, creep, stress relaxation, and physical aging of the polymer. The crystalline domains can serve as net points in the amorphous domains that restrict the freedom of movement of polymer chains in the amorphous domain. As a result, physical aging, creep, and stress relaxation can be reduced. In addition, for the reasons discussed above, the toughness of the polymer is also increased.
In general, both microparticles and nanoparticles can be used as nucleation points. However, as the number of particles increases and size of the particles decreases, the crystalline domains become more effective in increasing fracture toughness and reducing physical aging, creep, and stress relaxation. The closer the crystalline domains are to one another within the amorphous domain of a polymer, the more the crystalline domains can limit the degree of freedom movement of polymer chains in the amorphous domain. Therefore, nanoparticles may be more effective in reducing physical aging, creep, and stress relaxation.
In certain embodiments, the size of the crystalline domains can be controlled by the temperature of the cooling polymer construct from an extruder. In general, crystallization tends to occur in a polymer at temperatures between Tg and Tm of the polymer. The rate of crystallization in this range varies with temperature.
In certain embodiments, the temperature of the cooling polymer construct can be at a temperature at which the overall crystallization rate is relatively low. At such a temperature, the increase in crystallinity is predominantly due to formation of crystalline domains around the bioceramic particles, rather than the growth of existing crystals. In some embodiments, the temperature can be in a range in which the crystal nucleation rate is larger than the crystal growth rate. In one embodiment, the temperature can be in a range in which the crystal nucleation rate is substantially larger than the crystal growth rate. For example, the temperature can be where the ratio of the crystal nucleation rate to crystal growth rate is 2, 5, 10, 50, 100, or greater than 100. In another embodiment, the temperature range may be in range, ΔT, shown in
In general, good bonding between a continuous phase and a discrete or reinforcing phase in a composite material facilitates improvement of the mechanical performance of the composite. For example, increase of the modulus and fracture toughness of a polymer due to a bioceramic particle phase can be enhanced by good bonding between the polymer and particles.
In some embodiments, bioceramic particles may include an adhesion promoter to improve the adhesion between the particles and the polymer matrix. In one embodiment, an adhesion promoter can include a coupling agent. A coupling agent refers to a chemical substance capable of reacting with both the bioceramic particle and the polymer matrix of the composite material. A coupling agent acts as an interface between the polymer and the bioceramic particle to form a chemical bridge between the two to enhance adhesion.
The adhesion promoter may include, but is not limited to, silane and non-silane coupling agents. For example, the adhesion promoter may include 3-aminopropyltrimethoxysilane, 3-aminopropyltriethoxysilane, aminopropylmethyldiethoxy silane, organotrialkoxysilanes, titanates, zirconates, and organic acid-chromium chloride coordination complexes. In particular, 3-aminopropyltrimethoxysilane has been shown to facilitate adhesion between poly(L-lactide) and bioglass. Biomaterials 25 (2004) 2489-2500.
In some embodiments, the surface of the bioceramic particles may be treated with an adhesion promoter prior to mixing with the polymer matrix. In one embodiment, the bioceramic particles can be treated with a solution containing the adhesion promoter. Treating can include, but is not limited to, coating, dipping, or spraying the particles with an adhesion promoter or a solution including the adhesion promoter. The particles can also be treated with a gas containing the adhesion promoter. In one embodiment, treatment of the bioceramic particles includes mixing the adhesion promoter with solution of distilled water and a solvent such as ethanol and then adding bioceramic particles. The bioceramic particles can then be separated from the solution, for example, by a centrifuge, and the particles can be dried. The bioceramic particles may then used to form a polymer composite. In an alternative embodiment, the adhesion promoter can be added to the particles during formation of the composite. For example, the adhesion promoter can be mixed with a bioceramic/polymer mixture during extrusion.
As indicated above, a device may be composed in whole or in part of materials that degrade, erode, or disintegrate through exposure to physiological conditions within the body until the treatment regimen is completed. The device may be configured to disintegrate and disappear from the region of implantation once treatment is completed. The device may disintegrate by one or more mechanisms including, but not limited to, dissolution and chemical breakdown.
The duration of a treatment period depends on the bodily disorder that is being treated. For illustrative purposes only, in treatment of coronary heart disease involving use of stents in diseased vessels, the duration can be in a range from about a month to a few years. However, the duration is typically in a range from about six to twelve months. Thus, it is desirable for an implantable medical device, such as a stent, to have a degradation time at or near the duration of treatment. Degradation time refers to the time for an implantable medical device to substantially or completely erode away from an implant site.
Several mechanisms may be relied upon for erosion and disintegration of implantable devices which include, but are not limited to, mechanical, chemical breakdown and dissolution. Therefore, bodily conditions can include, but are not limited to, all conditions associated with bodily fluids (contact with fluids, flow of fluids) and mechanical forces arising from body tissue in direct and indirect contact with a device. Degradation of polymeric materials principally involves chemical breakdown involving enzymatic and/or hydrolytic cleavage of device material due to exposure to bodily fluids such as blood.
Chemical breakdown of biodegradable polymers results in changes of physical and chemical properties of the polymer, for example, following exposure to bodily fluids in a vascular environment. Chemical breakdown may be caused by, for example, hydrolysis and/or metabolic processes. Hydrolysis is a chemical process in which a molecule is cleaved into two parts by the addition of a molecule of water. Consequently, the degree of degradation in the bulk of a polymer is strongly dependent on the diffusivity, and hence the diffusion rate of water in the polymer.
Another deficiency of some biodegradable polymers, such as poly(L-lactide), is that the degradation rate is slow and results in a degradation time of a stent outside of the desired range. A preferred degradation is from six to twelve months. Increasing the equilibrium content of moisture in a biodegradable polymer that degrades by hydrolysis can increase the degradation rate of a polymer. Various embodiments of the present invention include increasing the equilibrium moisture content in a polymer of a device to accelerate the degradation rate.
In some embodiments, bioabsorbable bioceramic particles may be included in a bioceramic/polymer composite device to increase the degradation time of the polymer of the device. In an embodiment, the degradation rate of a bioceramic/polymer composite device can be tuned and/or adjusted to a desired time frame. As the bioceramic particle erodes within the polymeric matrix, the porosity of the matrix increases. The increased porosity increases the diffusion rate of moisture through the polymeric matrix, and thus, the equilibrium moisture content of the polymeric matrix. As a result, the degradation rate of the polymer is increased. The porous structure also increases the transport of degradation products out of the matrix, which also increases the degradation rate of the matrix.
In certain embodiments, the degradation rate and degradation time of the device can be tuned or controlled through variables such as the type of bioceramic material and the size and shape of particles. In some embodiments, bioceramic materials can be selected to have a higher degradation rate than the polymer matrix. The faster the degradation rate of the bioceramic material, the faster the porosity of the polymer matrix increases which results in a greater increase in the degradation rate of the polymer matrix. Additionally, the size of the particles influence the time for erosion of the particles. The smaller the particles, the faster the erosion of the particles because of the higher surface area per unit mass of particles.
For example, nanoparticles may have a relatively fast erosion rate compared to microparticles. Additionally, elongated particles, such as fibers, may tend to erode faster on a per unit mass basis due to the higher surface area per unit mass of the particle. Also, short fibers may tend to erode faster than longer fibers. Short fibers refer to long fibers than have been cut into short lengths. In some embodiments, the short fibers may be made by forming fibers as described above, and cutting them into short lengths. In one embodiment, a length of at least a portion of the short fibers is substantially smaller than a diameter of the formed tube. For example, in some embodiments, the short fibers may be less than 0.05 mm long. In other embodiments, the short fibers may be between 0.05 and 8 mm long, or more narrowly between 0.1 and 0.4 mm long or 0.3 and 0.4 mm long.
Furthermore, the size and distribution of pores created by erosion of bioceramic particles can also influence the degradation rate and time of the polymer matrix. Smaller particles, such as nanoparticles, create a porous network that exposes a larger volume of polymer matrix to bodily fluid than larger particles, like microparticles. As a result the degradation rate and time of the matrix may be higher when nanoparticles are used rather than microparticles.
Through appropriate selection of the type of material for the particles and the size and shape of the particles, the particles and the device can be designed to have a selected erosion rates and degradation time. For example, the particles can designed erode away in several minutes, hours, days, or a month upon exposure to bodily fluid.
As indicated above, many biodegradable polymers degrade by the mechanism of hydrolysis. The rate of the hydrolysis reaction tends to increase as the pH decreases. Since the degradation products of such polymers as polylactides are acidic, the degradation products have an autocatalytic effect. Therefore, the pH of the degradation products of the bioceramics can also affect the degradation rate of a device. Therefore, bioceramic particles with acidic degradation by-products may further increase the rate of degradation of a matrix polymer.
For example, tricalcium phosphate releases acidic degradation products. Thus, some embodiments may include a composite including a bioceramic having acidic degradation products upon exposure to bodily fluids. The acidic degradation products can increase the degradation rate of the polymer which can decrease the degradation time of the device.
In other embodiments, a composite can have bioceramic particles that have basic degradation products. For example, hydroxyapatite releases basic degradation products. The basic degradation products of the bioceramic particles can reduce the autocatalytic effect of the polymer degradation by neutralizing the acidic degradation products of the polymer degradation. In some embodiments, the basic degradation products of the bioceramic particles can reduce the degradation rate of the polymer. Additionally, bioceramic particles having a basic degradation product may also depress foreign body reaction.
For example, in rapidly eroding implantable medical devices, such as, for example poly(lactide-co-glycolide) which can potentially produce a local pH drop due to the rapid release of acidic degradation products, the use of bioceramic particles having a basic degradation product may buffer the reaction and neutralize the local pH drop.
Further embodiments of the invention include formation of a bioceramic/polymer composite and fabrication of an implantable medical device therefrom. As indicated above, a composite of a polymer and bioceramic particles can be extruded to form a polymer construct, such as a tube. A stent can then be fabricated from the tube. The composite can be formed in a number of ways. In some embodiments, the composite can be formed by melt blending. In melt blending the bioceramic particles are mixed with a polymer melt. The particles can be mixed with the polymer melt using extrusion or batch processing.
In one embodiment, the bioceramic particles can be combined with a polymer in a powdered or granular form prior to melting of the polymer. The particles and polymer can be mixed using mechanical mixing or stirring such as agitation of the particles and polymer in a container or a mixer. The agitated mixture can then be heated to a temperature above the melt temperature of the polymer in an extruder or using batch processing.
However, a problem with the mechanical mixing or stirring techniques is that the polymer and particles may be separated into separate regions or layers. This is particularly a problem with respect to smaller particles such as nanoparticles. Additionally, obtaining a uniform dispersion by mixing particles with a polymer melt as described, is that particles can agglomerate or form clusters. The mechanical mixing in an extruder or in batch processing can be insufficient to break up the clusters, resulting in a nonuniform mixture of bioceramic particles and polymer. Some embodiments may include forming a composite from a suspension of bioceramic particles and a polymer solution. A composite formed using a suspension may result in a composite having more uniformly dispersed particles than methods formed without using a suspension.
Alternatively, bioceramic particles can be mixed with a polymer by solution blending in which a composite mixture of bioceramic particles and polymer is formed from a suspension of particles in a polymer solution. Certain embodiments of a method of forming an implantable medical device may include forming a suspension including a fluid, a polymer, and bioceramic particles. A “suspension” is a mixture in which particles are suspended or dispersed in a fluid. The fluid can be a solvent for the polymer so that the polymer is dissolved in the fluid. The particles can be mixed with the fluid before or after dissolving the polymer in the fluid.
Various mechanical mixing methods known to those of skill in the art may be used to disperse the bioceramic particles in the suspension. In one embodiment, the suspension can be treated with ultrasound, for example, by an ultrasonic mixer.
The method may further include combining the suspension with a second fluid that may be a poor solvent for the polymer. At least some of polymer may be allowed to precipitate upon combining the suspension solution with the second fluid. In some embodiments, at least some of the bioceramic particles may precipitate from the suspension with the precipitated polymer to form a composite mixture.
The precipitated composite mixture may then be filtered out of the solvents. The filtered composite mixture can be dried to remove residual solvents. For example, the composite mixture can be dried in a vacuum oven or by blowing heated gas on the mixture.
Exemplary polymers may include, but are not limited to, poly (L-lactic acid), poly (DL-lactic acid), poly (lactide-coglycolide). Representative solvents for such polymers can include toluene and chloroform. Representative poor solvents for these polymers that may be used to precipitate the polymer include methanol, ethanol, isopropanol, and various alkanes such as hexane or heptane.
It is believed that in a suspension including bioceramic nanoparticles, the particles can have strong interactions with polymer chains in solution which can result in particles becoming encapsulated or surrounded by polymer chains. Thus, when the polymer is precipitated from the solution, the interactions of the particles with the polymer can overcome interactions of the particles with the solution so that the particles precipitate with the polymer.
Additionally, it has been observed that the both the degree of precipitation of particles and the degree of dispersion of particles within the precipitated polymer depends upon the amount of polymer dissolved in the solution. The degree of precipitation refers to the amount of particles that precipitate out of the suspension. The degree of dispersion of particles within the precipitated polymer refers to the degree of mixing of the particles with the polymer.
The amount of polymer can be quantified by the weight percent of the polymer in the suspension solution. In addition, the viscosity of the solution is also related to the amount of polymer in the solution. The higher the weight percent of dissolved polymer, the higher is the viscosity of the suspension solution.
For a given concentration of suspended particles, as weight percent of dissolved polymer or viscosity is reduced, the degree of precipitation of particles is reduced. This is likely due to the reduced interaction of the particles with the polymer chains. Thus, at lower weight percent of polymer or viscosity, the amount of particles precipitating can be relatively low.
Additionally, for a given concentration of suspended particles, as the weight percent of polymer or viscosity of the solution is increased beyond an observed range, the degree of dispersion of particles in the precipitated polymer tends to decrease. It is believed that at higher weight percent of polymer or higher viscosity, the interactions between polymer chains reduce the interaction of particles with polymer chains that cause particles to precipitate. For example, particles may be unable to move freely among the polymer chains.
A given suspension can have a particular combination of type of particles, particle concentration, and solvent. For this given suspension, the polymer weight percent or viscosity that can be varied to obtain both a desired degree of precipitation of particles and degree of dispersion of particles in the precipitated polymer. Thus, there may be a range of polymer weight percent or viscosity that can result in a desired degree of precipitation of particles and degree of dispersion of particles in precipitated polymer.
Additionally, the manner of combining the suspension with the poor solvent can also affect the degree of precipitation and degree of dispersion. For example, depositing a fine mist of small droplets into a poor solvent can more readily result in a desired degree of precipitation and degree of dispersion. Thus, the manner of combining the suspension with the poor solvent can influence the range of polymer weight percent or viscosity that results in a desired degree of precipitation and degree of dispersion.
Further embodiments of the method include conveying the composite mixture into an extruder. The composite mixture may be extruded at a temperature above the melting temperature of the polymer and less than the melting temperature of the bioceramic particles. In some embodiments, the dried composite mixture may be broken into small pieces by, for example, chopping or grinding. Extruding smaller pieces of the composite mixture may lead to a more uniform distribution of the nanoparticles during the extrusion process.
The extruded composite mixture may then be formed into a polymer construct, such as a tube or sheet which can be rolled or bonded to form a tube. A medical device may then be fabricated from the construct. For example, a stent can be fabricated from a tube by laser machining a pattern in to the tube.
In another embodiment, a polymer construct may be formed from the composite mixture using an injection molding apparatus.
Preparation of a desired amount of precipitated composite mixture may require a large amount of solvent and precipitant. Therefore, in some embodiments, it may be advantageous to melt blend precipitated composite mixture with an amount of polymer in an extruder or in a batch process. The polymer can be the same or a different polymer of the precipitated composite mixture. For example, a relatively small amount of precipitated composite mixture that has a weight percent of bioceramic particles higher than is desired can be prepared. The precipitated composite mixture may be melt blended with an amount of biodegradable polymer to form a composite mixture than has a desired weight percent of bioceramic particles.
Representative examples of polymers that may be used to fabricate an implantable medical device include, but are not limited to, poly(N-acetylglucosamine) (Chitin), Chitosan, poly(hydroxyvalerate), poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polyorthoester, polyanhydride, poly(glycolic acid), poly(glycolide), poly(L-lactic acid), poly(L-lactide), poly(D,L-lactic acid), poly(L-lactide-co-glycolide); poly(D,L-lactide), poly(caprolactone), poly(trimethylene carbonate), polyethylene amide, polyethylene acrylate, poly(glycolic acid-co-trimethylene carbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers other than polyacrylates, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), acrylonitrile-styrene copolymers, ABS resins, polyamides (such as Nylon 66 and polycaprolactam), polycarbonates, polyoxymethylenes, polyimides, polyethers, polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, and carboxymethyl cellulose.
Additional representative examples of polymers that may be especially well suited for use in fabricating an implantable medical device according to the methods disclosed herein include ethylene vinyl alcohol copolymer (commonly known by the generic name EVOH or by the trade name EVAL), poly(butyl methacrylate), poly(vinylidene fluoride-co-hexafluororpropene) (e.g., SOLEF 21508, available from Solvay Solexis PVDF, Thorofare, N.J.), polyvinylidene fluoride (otherwise known as KYNAR, available from ATOFINA Chemicals, Philadelphia, Pa.), ethylene-vinyl acetate copolymers, and polyethylene glycol.
The examples and experimental data set forth below are for illustrative purposes only and are in no way meant to limit the invention. The following examples are given to aid in understanding the invention, but it is to be understood that the invention is not limited to the particular materials or procedures of examples. In all examples, hydroxyapatite nano particles (HAP) are used as one typical bioceramic nanoparticle. The polymers used in the Examples were poly (L-lactic acid) (PLLA), poly (DL-lactic acid) (PDLLA), and poly (lactic acid co-glycolide) (PLGA).
Step 1: Add bioceramic particles into suitable solvent, such as chloroform, acetone, etc. and stir to form a bioceramic particle suspension solution.
Step 2: Slowly add a polymer such as PLLA, PDLLA, PGLA into suspension solution and stir until polymer dissolves completely. In this step, the solution may still have a relatively low viscosity. However, the bioceramic particles should be well dispersed while stirring.
Step 3: Slowly add the polymer into solution again to gradually increase solution viscosity. Repeat this step as needed until the polymer is completely dissolved and reasonable solution viscosity is developed.
Step 4: Apply ultrasonic mixing to suspension solution for 15-30 min to further disperse all the HAP uniformly into the PLLA solution.
Step 6: Add suspension solution to IL methanol to precipitate polymer and particles.
Solution Blending of PLLA/HAP Composite (100:1 wt/wt)
Step 1: Added 50 mg HAP particles into 300 mL of chloroform and stirred for 10-30 minutes to form bioceramic particle suspension solution.
Step 2: Slowly added 5 g PLLA into suspension solution and stirred about 8 hours to dissolve all polymer.
Step 3: Applied ultrasonic mixing to suspension solution for 15-30 min to further disperse HAP particles into PLLA solution.
Step 4: Added suspension solution to 1L methanol to precipitate polymer and particles.
Step 5: Filtered the precipitate and dried about 8 hours in vacuum oven at 60° C. End product is PLLA/HAP composite. Composites were also made with 2 wt % and 5 wt % HAP.
Mechanical Properties and Morphology of PLLA/HAP Composite (100:1 wt/wt)
Tensile testing of the composite samples and a pure PLLA were performed using an Instron tensile tester. Test samples were prepared by hot pressing the PLLA/HAP composites and pure polymer to a thin film at 193° C. for 30 seconds. Testing bars were cut from the thin film and tested. The peak stress at break, the strain at break, and the Young's modulus were measured. The draw rate was about 0.5 in/min.
Solution Blending of PLLA/HAP Composite (2:1 wt/wt) as HAP Intermedium Mixture
Step 1: Added 25 g HAP particles to 3L chloroform and stirred for 10-30 minutes to form bioceramic particle suspension solution.
Step 2: Slowly added 50 g PLLA into suspension solution and stirred about 8 hours to dissolve all polymer.
Step 3: Applied ultrasonic mixing for 15-30 min to further disperse HAP particles into PLLA solution.
Step 4: Added suspension solution to 9L methanol to precipitate particles and polymer.
Step 5: Filtered the precipitate and dried about 8 hours in vacuum oven at 60° C. End product is PLLA/HAP composite.
Extrusion of Precipitated PLLA/HAP (2:1 wt/wt) with PLLA
Step 1: Broke 2:1 wt/wt composite into small pieces
Step 2: Mixed 24 g of broken up composite and 376 g PLLA.
Step 3: Extruded mixture at 216° C.
Extrusion of Precipitated PLGA/HAP (2:1 wt/wt) with PLGA
Step 1: Broke PLGA/HAP composite into small pieces
Step 2: Mixed 12 g broken up PLGA/HAP composite and 396 g PLGA.
Step 3: Extruded mixture at 216° C.
As discussed above, to further improve mechanical properties of a bioceramic and polymer composite, the interfacial adhesion can be enhanced. The adhesion between bioceramic particles and a biodegradable polymer can be improved by coating at least a portion of the surfaces of the bioceramic particles with an adhesion promoter such as 3-aminopropyltrimethoxysilane and 3-aminopropyltriethoxysilane.
Example of the Modification of HAP:
Step 1: Added 100 ml distillated water to 1900 ml Ethanol and stirred for 15-30 min.
Step 2: Added 20 g 3-aminopropyltrimethoxysilane to water-ethanol mixture and stirred for 1 h.
Step 3: Added 20 g HAP and stirred for 2 h.
Step 4: Centrifuged the modified HAP from solution.
Step 5: Dried HAP about 8 hours in vacuum oven.
A stent was fabricated from a PLGA/nanoparticle composite tubing. Prior to cutting a stent pattern, the tubing was expanded at 109° C. in a blow molder to increase radial strength. A stent pattern was cut in the expanded tubing using an ultra-fast pulse laser. The stent was crimped at 30° C. After crimping, the stent was cold sterilized.
The mechanical properties of a stent fabricated from a PLGA/nanoparticle HAP composite were tested on an Instron compression tester. The recoil of stents was recorded after inflation and deflation of stent.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.
|US3687135||15. Sept. 1969||29. Aug. 1972||Evgeny Mikhailovich Savitsky||Magnesium-base alloy for use in bone surgery|
|US3737337||9. Febr. 1971||5. Juni 1973||Bayer Ag||Process for the production of microgranulates|
|US3839743||15. Okt. 1973||8. Okt. 1974||A Schwarcz||Method for maintaining the normal integrity of blood|
|US3900632||3. Apr. 1972||19. Aug. 1975||Kimberly Clark Co||Laminate of tissue and random laid continuous filament web|
|US4104410||9. Sept. 1976||1. Aug. 1978||Malecki George J||Processing of green vegetables for color retention in canning|
|US4110497||2. Juli 1976||29. Aug. 1978||Snyder Manufacturing Co., Ltd.||Striped laminate and method and apparatus for making same|
|US4321711||12. Okt. 1979||30. März 1982||Sumitomo Electric Industries, Ltd.||Vascular prosthesis|
|US4346028||24. Nov. 1980||24. Aug. 1982||Monsanto Company||Asbestiform crystalline calcium sodium or lithium phosphate, preparation and compositions|
|US4596574||14. Mai 1984||24. Juni 1986||The Regents Of The University Of California||Biodegradable porous ceramic delivery system for bone morphogenetic protein|
|US4599085||1. Febr. 1984||8. Juli 1986||Neodontics, Inc.||Bone implant member for prostheses and bone connecting elements and process for the production thereof|
|US4612009||11. Juni 1985||16. Sept. 1986||Ceskoslovenska Akademie Ved||Biodegradable implant and a method for preparation thereof|
|US4633873||26. Apr. 1984||6. Jan. 1987||American Cyanamid Company||Surgical repair mesh|
|US4656083||11. März 1985||7. Apr. 1987||Washington Research Foundation||Plasma gas discharge treatment for improving the biocompatibility of biomaterials|
|US4718907||20. Juni 1985||12. Jan. 1988||Atrium Medical Corporation||Vascular prosthesis having fluorinated coating with varying F/C ratio|
|US4722335||20. Okt. 1986||2. Febr. 1988||Vilasi Joseph A||Expandable endotracheal tube|
|US4723549||18. Sept. 1986||9. Febr. 1988||Wholey Mark H||Method and apparatus for dilating blood vessels|
|US4732152||5. Dez. 1985||22. März 1988||Medinvent S.A.||Device for implantation and a method of implantation in a vessel using such device|
|US4733665||7. Nov. 1985||29. März 1988||Expandable Grafts Partnership||Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft|
|US4739762||3. Nov. 1986||26. Apr. 1988||Expandable Grafts Partnership||Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft|
|US4740207||10. Sept. 1986||26. Apr. 1988||Kreamer Jeffry W||Intralumenal graft|
|US4743252||13. Jan. 1986||10. Mai 1988||Corvita Corporation||Composite grafts|
|US4768507||31. Aug. 1987||6. Sept. 1988||Medinnovations, Inc.||Intravascular stent and percutaneous insertion catheter system for the dilation of an arterial stenosis and the prevention of arterial restenosis|
|US4776337||26. Juni 1986||11. Okt. 1988||Expandable Grafts Partnership||Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft|
|US4800882||13. März 1987||31. Jan. 1989||Cook Incorporated||Endovascular stent and delivery system|
|US4816339||28. Apr. 1987||28. März 1989||Baxter International Inc.||Multi-layered poly(tetrafluoroethylene)/elastomer materials useful for in vivo implantation|
|US4818559||29. Juli 1986||4. Apr. 1989||Sumitomo Chemical Company, Limited||Method for producing endosseous implants|
|US4850999||26. Mai 1981||25. Juli 1989||Institute Fur Textil-Und Faserforschung Of Stuttgart||Flexible hollow organ|
|US4877030||31. Mai 1988||31. Okt. 1989||Andreas Beck||Device for the widening of blood vessels|
|US4878906||6. Juni 1988||7. Nov. 1989||Servetus Partnership||Endoprosthesis for repairing a damaged vessel|
|US4879135||18. Juli 1988||7. Nov. 1989||University Of Medicine And Dentistry Of New Jersey||Drug bonded prosthesis and process for producing same|
|US4886062||19. Okt. 1987||12. Dez. 1989||Medtronic, Inc.||Intravascular radially expandable stent and method of implant|
|US4902289||9. Aug. 1988||20. Febr. 1990||Massachusetts Institute Of Technology||Multilayer bioreplaceable blood vessel prosthesis|
|US4977901||6. Apr. 1990||18. Dez. 1990||Minnesota Mining And Manufacturing Company||Article having non-crosslinked crystallized polymer coatings|
|US4994298||18. Apr. 1990||19. Febr. 1991||Biogold Inc.||Method of making a biocompatible prosthesis|
|US5019090||1. Sept. 1988||28. Mai 1991||Corvita Corporation||Radially expandable endoprosthesis and the like|
|US5028597||13. Apr. 1990||2. Juli 1991||Agency Of Industrial Science And Technology||Antithrombogenic materials|
|US5059211||25. Juni 1987||22. Okt. 1991||Duke University||Absorbable vascular stent|
|US5062829||16. März 1990||5. Nov. 1991||Carter Holt Harvey Plastic Products Group Limited||Relates to devices for administering a substance such as a drug or chemical or the like|
|US5084065||10. Juli 1989||28. Jan. 1992||Corvita Corporation||Reinforced graft assembly|
|US5085629||27. Sept. 1989||4. Febr. 1992||Medical Engineering Corporation||Biodegradable stent|
|US5100429||20. Okt. 1989||31. März 1992||C. R. Bard, Inc.||Endovascular stent and delivery system|
|US5104410||22. Okt. 1990||14. Apr. 1992||Intermedics Orthopedics, Inc||Surgical implant having multiple layers of sintered porous coating and method|
|US5108417||14. Sept. 1990||28. Apr. 1992||Interface Biomedical Laboratories Corp.||Anti-turbulent, anti-thrombogenic intravascular stent|
|US5108755||27. Apr. 1989||28. Apr. 1992||Sri International||Biodegradable composites for internal medical use|
|US5112457||23. Juli 1990||12. Mai 1992||Case Western Reserve University||Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants|
|US5123917||27. Apr. 1990||23. Juni 1992||Lee Peter Y||Expandable intraluminal vascular graft|
|US5156623||5. Apr. 1991||20. Okt. 1992||Olympus Optical Co., Ltd.||Sustained release material and method of manufacturing the same|
|US5163951||27. März 1992||17. Nov. 1992||Corvita Corporation||Mesh composite graft|
|US5163952||14. Sept. 1990||17. Nov. 1992||Michael Froix||Expandable polymeric stent with memory and delivery apparatus and method|
|US5163958||13. Aug. 1991||17. Nov. 1992||Cordis Corporation||Carbon coated tubular endoprosthesis|
|US5167614||29. Okt. 1991||1. Dez. 1992||Medical Engineering Corporation||Prostatic stent|
|US5192311||13. Aug. 1990||9. März 1993||Angeion Corporation||Medical implant and method of making|
|US5197977||30. Apr. 1992||30. März 1993||Meadox Medicals, Inc.||Drug delivery collagen-impregnated synthetic vascular graft|
|US5234456||7. Mai 1992||10. Aug. 1993||Pfizer Hospital Products Group, Inc.||Hydrophilic stent|
|US5234457||9. Okt. 1991||10. Aug. 1993||Boston Scientific Corporation||Impregnated stent|
|US5236447||28. Juni 1991||17. Aug. 1993||Nissho Corporation||Artificial tubular organ|
|US5279594||23. Mai 1990||18. Jan. 1994||Jackson Richard R||Intubation devices with local anesthetic effect for medical use|
|US5282860||8. Okt. 1992||1. Febr. 1994||Olympus Optical Co., Ltd.||Stent tube for medical use|
|US5289831||21. Apr. 1992||1. März 1994||Vance Products Incorporated||Surface-treated stent, catheter, cannula, and the like|
|US5290271||29. Juli 1993||1. März 1994||Jernberg Gary R||Surgical implant and method for controlled release of chemotherapeutic agents|
|US5306286||1. Febr. 1991||26. Apr. 1994||Duke University||Absorbable stent|
|US5306294||5. Aug. 1992||26. Apr. 1994||Ultrasonic Sensing And Monitoring Systems, Inc.||Stent construction of rolled configuration|
|US5328471||4. Aug. 1993||12. Juli 1994||Endoluminal Therapeutics, Inc.||Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens|
|US5330500||17. Okt. 1991||19. Juli 1994||Song Ho Y||Self-expanding endovascular stent with silicone coating|
|US5342348||4. Dez. 1992||30. Aug. 1994||Kaplan Aaron V||Method and device for treating and enlarging body lumens|
|US5342395||13. Jan. 1992||30. Aug. 1994||American Cyanamid Co.||Absorbable surgical repair devices|
|US5342621||15. Sept. 1992||30. Aug. 1994||Advanced Cardiovascular Systems, Inc.||Antithrombogenic surface|
|US5356433||3. Nov. 1993||18. Okt. 1994||Cordis Corporation||Biocompatible metal surfaces|
|US5383925||14. Sept. 1992||24. Jan. 1995||Meadox Medicals, Inc.||Three-dimensional braided soft tissue prosthesis|
|US5385580||21. Sept. 1992||31. Jan. 1995||Meadox Medicals, Inc.||Self-supporting woven vascular graft|
|US5389106||29. Okt. 1993||14. Febr. 1995||Numed, Inc.||Impermeable expandable intravascular stent|
|US5399666||21. Apr. 1994||21. März 1995||E. I. Du Pont De Nemours And Company||Easily degradable star-block copolymers|
|US5407609||17. Mai 1993||18. Apr. 1995||Southern Research Institute||Microencapsulation process and products therefrom|
|US5423885||14. Juli 1993||13. Juni 1995||Advanced Cardiovascular Systems, Inc.||Stent capable of attachment within a body lumen|
|US5441515||23. Apr. 1993||15. Aug. 1995||Advanced Cardiovascular Systems, Inc.||Ratcheting stent|
|US5443458||3. Dez. 1993||22. Aug. 1995||Advanced Cardiovascular Systems, Inc.||Multilayered biodegradable stent and method of manufacture|
|US5443500||8. Apr. 1994||22. Aug. 1995||Advanced Cardiovascular Systems, Inc.||Intravascular stent|
|US5455040||19. Nov. 1992||3. Okt. 1995||Case Western Reserve University||Anticoagulant plasma polymer-modified substrate|
|US5464650||26. Apr. 1993||7. Nov. 1995||Medtronic, Inc.||Intravascular stent and method|
|US5502158||22. Sept. 1992||26. März 1996||Ecopol, Llc||Degradable polymer composition|
|US5514379||7. Aug. 1992||7. Mai 1996||The General Hospital Corporation||Hydrogel compositions and methods of use|
|US5527337||22. Febr. 1994||18. Juni 1996||Duke University||Bioabsorbable stent and method of making the same|
|US5545408||19. Okt. 1992||13. Aug. 1996||Peptide Technology Limited||Biocompatible implant for the timing of ovulation in mares|
|US5554120||25. Juli 1994||10. Sept. 1996||Advanced Cardiovascular Systems, Inc.||Polymer blends for use in making medical devices including catheters and balloons for dilatation catheters|
|US5556413||11. März 1994||17. Sept. 1996||Advanced Cardiovascular Systems, Inc.||Coiled stent with locking ends|
|US5578046||12. Mai 1995||26. Nov. 1996||United States Surgical Corporation||Composite bioabsorbable materials and surgical articles made thereform|
|US5578073||16. Sept. 1994||26. Nov. 1996||Ramot Of Tel Aviv University||Thromboresistant surface treatment for biomaterials|
|US5591199||7. Juni 1995||7. Jan. 1997||Porter; Christopher H.||Curable fiber composite stent and delivery system|
|US5591607||6. Juni 1995||7. Jan. 1997||Lynx Therapeutics, Inc.||Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation|
|US5593403||14. Sept. 1994||14. Jan. 1997||Scimed Life Systems Inc.||Method for modifying a stent in an implanted site|
|US5593434||7. Juni 1995||14. Jan. 1997||Advanced Cardiovascular Systems, Inc.||Stent capable of attachment within a body lumen|
|US5599301||22. Nov. 1993||4. Febr. 1997||Advanced Cardiovascular Systems, Inc.||Motor control system for an automatic catheter inflation system|
|US5599922||18. März 1994||4. Febr. 1997||Lynx Therapeutics, Inc.||Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties|
|US5605696||30. März 1995||25. Febr. 1997||Advanced Cardiovascular Systems, Inc.||Drug loaded polymeric material and method of manufacture|
|US5607442||13. Nov. 1995||4. März 1997||Isostent, Inc.||Stent with improved radiopacity and appearance characteristics|
|US5607467||23. Juni 1993||4. März 1997||Froix; Michael||Expandable polymeric stent with memory and delivery apparatus and method|
|US5618299||8. Aug. 1995||8. Apr. 1997||Advanced Cardiovascular Systems, Inc.||Ratcheting stent|
|US5626861||1. Apr. 1994||6. Mai 1997||Massachusetts Institute Of Technology||Polymeric-hydroxyapatite bone composite|
|US5629077||27. Juni 1994||13. Mai 1997||Advanced Cardiovascular Systems, Inc.||Biodegradable mesh and film stent|
|US5631135||6. Juni 1995||20. Mai 1997||Lynx Therapeutics, Inc.||Oligonucleotide N3'→P5' phosphoramidates: hybridization and nuclease resistance properties|
|US5632771||25. Jan. 1995||27. Mai 1997||Cook Incorporated||Flexible stent having a pattern formed from a sheet of material|
|US5632840||6. Juni 1995||27. Mai 1997||Advanced Cardiovascular System, Inc.||Method of making metal reinforced polymer stent|
|US5637113||13. Dez. 1994||10. Juni 1997||Advanced Cardiovascular Systems, Inc.||Polymer film for wrapping a stent structure|
|US5649977||22. Sept. 1994||22. Juli 1997||Advanced Cardiovascular Systems, Inc.||Metal reinforced polymer stent|
|US5667767||27. Juli 1995||16. Sept. 1997||Micro Therapeutics, Inc.||Compositions for use in embolizing blood vessels|
|US5667796||5. Juni 1996||16. Sept. 1997||Otten; Klaus||Method for producing ceramic implant materials, preferably ceramic implant materials including hydroxyl apatite|
|US5670558||6. Juli 1995||23. Sept. 1997||Terumo Kabushiki Kaisha||Medical instruments that exhibit surface lubricity when wetted|
|US5693085||26. Apr. 1995||2. Dez. 1997||Scimed Life Systems, Inc.||Stent with collagen|
|US5700286||22. Aug. 1996||23. Dez. 1997||Advanced Cardiovascular Systems, Inc.||Polymer film for wrapping a stent structure|
|US5707385||16. Nov. 1994||13. Jan. 1998||Advanced Cardiovascular Systems, Inc.||Drug loaded elastic membrane and method for delivery|
|US5711763||30. Juni 1995||27. Jan. 1998||Tdk Corporation||Composite biological implant of a ceramic material in a metal substrate|
|US5716981||7. Juni 1995||10. Febr. 1998||Angiogenesis Technologies, Inc.||Anti-angiogenic compositions and methods of use|
|US5725549||12. Sept. 1996||10. März 1998||Advanced Cardiovascular Systems, Inc.||Coiled stent with locking ends|
|US5726297||5. Juni 1995||10. März 1998||Lynx Therapeutics, Inc.||Oligodeoxyribonucleotide N3' P5' phosphoramidates|
|US5728751||25. Nov. 1996||17. März 1998||Meadox Medicals, Inc.||Bonding bio-active materials to substrate surfaces|
|US5733326||28. Mai 1996||31. März 1998||Cordis Corporation||Composite material endoprosthesis|
|US5733330||13. Jan. 1997||31. März 1998||Advanced Cardiovascular Systems, Inc.||Balloon-expandable, crush-resistant locking stent|
|US5733564||12. Apr. 1994||31. März 1998||Leiras Oy||Method of treating endo-osteal materials with a bisphosphonate solution|
|US5733925||28. Okt. 1996||31. März 1998||Neorx Corporation||Therapeutic inhibitor of vascular smooth muscle cells|
|US5741881||25. Nov. 1996||21. Apr. 1998||Meadox Medicals, Inc.||Process for preparing covalently bound-heparin containing polyurethane-peo-heparin coating compositions|
|US5756457||5. Mai 1995||26. Mai 1998||Genetics Institute, Inc.||Neural regeneration using human bone morphogenetic proteins|
|US5756476||26. Jan. 1994||26. Mai 1998||The United States Of America As Represented By The Department Of Health And Human Services||Inhibition of cell proliferation using antisense oligonucleotides|
|US5765682||24. Juni 1996||16. Juni 1998||Menlo Care, Inc.||Restrictive package for expandable or shape memory medical devices and method of preventing premature change of same|
|US5766204||12. Sept. 1997||16. Juni 1998||Metastent Incorporated||Curable fiber composite stent and delivery system|
|US5766239||3. Okt. 1997||16. Juni 1998||Advanced Cardiovascular Systems, Inc.||Balloon-expandable, crush resistant locking stent and method of loading the same|
|US5766710||19. Juni 1996||16. Juni 1998||Advanced Cardiovascular Systems, Inc.||Biodegradable mesh and film stent|
|US5769883||21. Nov. 1995||23. Juni 1998||Scimed Life Systems, Inc.||Biodegradable drug delivery vascular stent|
|US5780807||15. Jan. 1997||14. Juli 1998||Advanced Cardiovascular Systems, Inc.||Method and apparatus for direct laser cutting of metal stents|
|US5800516||8. Aug. 1996||1. Sept. 1998||Cordis Corporation||Deployable and retrievable shape memory stent/tube and method|
|US5811447||25. Mai 1995||22. Sept. 1998||Neorx Corporation||Therapeutic inhibitor of vascular smooth muscle cells|
|US5824049||31. Okt. 1996||20. Okt. 1998||Med Institute, Inc.||Coated implantable medical device|
|US5830178||11. Okt. 1996||3. Nov. 1998||Micro Therapeutics, Inc.||Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide|
|US5830461||8. Nov. 1996||3. Nov. 1998||University Of Pittsburgh Of The Commonwealth System Of Higher Education||Methods for promoting wound healing and treating transplant-associated vasculopathy|
|US5830879||2. Okt. 1995||3. Nov. 1998||St. Elizabeth's Medical Center Of Boston, Inc.||Treatment of vascular injury using vascular endothelial growth factor|
|US5833651||8. Nov. 1996||10. Nov. 1998||Medtronic, Inc.||Therapeutic intraluminal stents|
|US5834582||20. Febr. 1996||10. Nov. 1998||Chronopol, Inc.||Degradable polymer composition|
|US5836962||22. Jan. 1997||17. Nov. 1998||Schneider (Europe) Ag||Endoprosthesis|
|US5837313||13. Juni 1996||17. Nov. 1998||Schneider (Usa) Inc||Drug release stent coating process|
|US5837835||6. Juni 1995||17. Nov. 1998||Lynx Therapeutics, Inc.||Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties|
|US5840083||15. Nov. 1996||24. Nov. 1998||F.B. Rice & Co.||Implant device having biocompatiable membrane coating|
|US5851508||14. Febr. 1997||22. Dez. 1998||Microtherapeutics, Inc.||Compositions for use in embolizing blood vessels|
|US5853408||1. Juni 1995||29. Dez. 1998||Advanced Cardiovascular Systems, Inc.||In-vivo modification of the mechanical properties of surgical devices|
|US5854207||23. Febr. 1998||29. Dez. 1998||Stryker Corporation||Compositions and therapeutic methods using morphogenic proteins and stimulatory factors|
|US5855612||10. Mai 1996||5. Jan. 1999||Ohta Inc.||Biocompatible titanium implant|
|US5855618||13. Sept. 1996||5. Jan. 1999||Meadox Medicals, Inc.||Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin|
|US5858746||25. Jan. 1995||12. Jan. 1999||Board Of Regents, The University Of Texas System||Gels for encapsulation of biological materials|
|US5865814||6. Aug. 1997||2. Febr. 1999||Medtronic, Inc.||Blood contacting medical device and method|
|US5868781||22. Okt. 1996||9. Febr. 1999||Scimed Life Systems, Inc.||Locking stent|
|US5873904||24. Febr. 1997||23. Febr. 1999||Cook Incorporated||Silver implantable medical device|
|US5874101||14. Apr. 1997||23. Febr. 1999||Usbiomaterials Corp.||Bioactive-gel compositions and methods|
|US5874109||4. Sept. 1997||23. Febr. 1999||The Trustees Of The University Of Pennsylvania||Incorporation of biological molecules into bioactive glasses|
|US5874165||27. Mai 1997||23. Febr. 1999||Gore Enterprise Holdings, Inc.||Materials and method for the immobilization of bioactive species onto polymeric subtrates|
|US5876743||22. Sept. 1997||2. März 1999||Den-Mat Corporation||Biocompatible adhesion in tissue repair|
|US5877263||25. Nov. 1996||2. März 1999||Meadox Medicals, Inc.||Process for preparing polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents|
|US5879713||23. Jan. 1997||9. März 1999||Focal, Inc.||Targeted delivery via biodegradable polymers|
|US5888533||21. Nov. 1997||30. März 1999||Atrix Laboratories, Inc.||Non-polymeric sustained release delivery system|
|US5891192||22. Mai 1997||6. Apr. 1999||The Regents Of The University Of California||Ion-implanted protein-coated intralumenal implants|
|US5897955||21. Aug. 1998||27. Apr. 1999||Gore Hybrid Technologies, Inc.||Materials and methods for the immobilization of bioactive species onto polymeric substrates|
|US5906759||26. Dez. 1996||25. Mai 1999||Medinol Ltd.||Stent forming apparatus with stent deforming blades|
|US5914182||3. Juni 1996||22. Juni 1999||Gore Hybrid Technologies, Inc.||Materials and methods for the immobilization of bioactive species onto polymeric substrates|
|US5916870||22. Sept. 1998||29. Juni 1999||Stryker Corporation||Compositions and therapeutic methods using morphogenic proteins and stimulatory factors|
|US5922005||21. Aug. 1998||13. Juli 1999||Medinol Ltd.||Stent fabrication method|
|US5942209||3. Nov. 1997||24. Aug. 1999||Focal, Inc.||Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel|
|US5948428||6. Dez. 1996||7. Sept. 1999||Stryker Corporation||Compositions and therapeutic methods using morphogenic proteins and stimulatory factors|
|US5954744||26. Juni 1997||21. Sept. 1999||Quanam Medical Corporation||Intravascular stent|
|US5957975||15. Dez. 1997||28. Sept. 1999||The Cleveland Clinic Foundation||Stent having a programmed pattern of in vivo degradation|
|US5965720||20. März 1995||12. Okt. 1999||Lynx Therapeutics, Inc.||Oligonucleotide N3'→P5' phosphoramidates|
|US5971954||29. Jan. 1997||26. Okt. 1999||Rochester Medical Corporation||Method of making catheter|
|US5976182||15. Juni 1998||2. Nov. 1999||Advanced Cardiovascular Systems, Inc.||Balloon-expandable, crush-resistant locking stent and method of loading the same|
|US5980564||1. Aug. 1997||9. Nov. 1999||Schneider (Usa) Inc.||Bioabsorbable implantable endoprosthesis with reservoir|
|US5980928||29. Juli 1997||9. Nov. 1999||Terry; Paul B.||Implant for preventing conjunctivitis in cattle|
|US5980972||22. Sept. 1997||9. Nov. 1999||Schneider (Usa) Inc||Method of applying drug-release coatings|
|US5981568||31. März 1997||9. Nov. 1999||Neorx Corporation||Therapeutic inhibitor of vascular smooth muscle cells|
|US5986169||31. Dez. 1997||16. Nov. 1999||Biorthex Inc.||Porous nickel-titanium alloy article|
|US5997468||4. Aug. 1997||7. Dez. 1999||Medtronic, Inc.||Intraluminal drug eluting prosthesis method|
|US6010445||12. Nov. 1997||4. Jan. 2000||Implant Sciences Corporation||Radioactive medical device and process|
|US6015541||3. Nov. 1997||18. Jan. 2000||Micro Therapeutics, Inc.||Radioactive embolizing compositions|
|US6042875||2. März 1999||28. März 2000||Schneider (Usa) Inc.||Drug-releasing coatings for medical devices|
|US6048964||12. Dez. 1995||11. Apr. 2000||Stryker Corporation||Compositions and therapeutic methods using morphogenic proteins and stimulatory factors|
|US6051648||13. Jan. 1999||18. Apr. 2000||Cohesion Technologies, Inc.||Crosslinked polymer compositions and methods for their use|
|US6056993||17. Apr. 1998||2. Mai 2000||Schneider (Usa) Inc.||Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel|
|US6060451||20. März 1995||9. Mai 2000||The National Research Council Of Canada||Thrombin inhibitors based on the amino acid sequence of hirudin|
|US6066156||11. März 1999||23. Mai 2000||Advanced Cardiovascular Systems, Inc.||Temperature activated adhesive for releasably attaching stents to balloons|
|US6071266||23. Okt. 1998||6. Juni 2000||Kelley; Donald W.||Lubricious medical devices|
|US6074659||10. Juli 1998||13. Juni 2000||Noerx Corporation||Therapeutic inhibitor of vascular smooth muscle cells|
|US6080177||28. Apr. 1998||27. Juni 2000||Igaki; Keiji||Luminal stent, holding structure therefor and device for attaching luminal stent|
|US6080488||24. März 1998||27. Juni 2000||Schneider (Usa) Inc.||Process for preparation of slippery, tenaciously adhering, hydrophilic polyurethane hydrogel coating, coated polymer and metal substrate materials, and coated medical devices|
|US6083258||28. Mai 1998||4. Juli 2000||Yadav; Jay S.||Locking stent|
|US6093463||20. März 1998||25. Juli 2000||Intella Interventional Systems, Inc.||Medical devices made from improved polymer blends|
|US6096070||16. Mai 1996||1. Aug. 2000||Med Institute Inc.||Coated implantable medical device|
|US6096525||26. Nov. 1997||1. Aug. 2000||Meadox Medicals, Inc.||Bonding bio-active materials to expanded polytetrafluoroethylene or polyethylene terephthalate via an isocyanate-terminated spacer|
|US6099562||22. Dez. 1997||8. Aug. 2000||Schneider (Usa) Inc.||Drug coating with topcoat|
|US6103230||2. Okt. 1998||15. Aug. 2000||University Of Pittsburgh Of The Commonwealth System Of Higher Education||Methods for promoting wound healing and treating transplant-associated vasculopathy|
|US6107416||1. Febr. 1999||22. Aug. 2000||Scimed Life Systems, Inc.||Polymer coatings grafted with polyethylene oxide chains containing covalently bonded bio-active agents|
|US6110188||9. März 1998||29. Aug. 2000||Corvascular, Inc.||Anastomosis method|
|US6113629||1. Mai 1998||5. Sept. 2000||Micrus Corporation||Hydrogel for the therapeutic treatment of aneurysms|
|US6117979||18. Aug. 1997||12. Sept. 2000||Medtronic, Inc.||Process for making a bioprosthetic device and implants produced therefrom|
|US6120536||13. Juni 1996||19. Sept. 2000||Schneider (Usa) Inc.||Medical devices with long term non-thrombogenic coatings|
|US6120904||24. Mai 1999||19. Sept. 2000||Schneider (Usa) Inc.||Medical device coated with interpenetrating network of hydrogel polymers|
|US6121027||15. Aug. 1997||19. Sept. 2000||Surmodics, Inc.||Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups|
|US6125523||20. Nov. 1998||3. Okt. 2000||Advanced Cardiovascular Systems, Inc.||Stent crimping tool and method of use|
|US6127173||22. Sept. 1998||3. Okt. 2000||Ribozyme Pharmaceuticals, Inc.||Nucleic acid catalysts with endonuclease activity|
|US6129761||7. Juni 1995||10. Okt. 2000||Reprogenesis, Inc.||Injectable hydrogel compositions|
|US6129928||4. Sept. 1998||10. Okt. 2000||Icet, Inc.||Biomimetic calcium phosphate implant coatings and methods for making the same|
|US6150630||17. Apr. 1998||21. Nov. 2000||The Regents Of The University Of California||Laser machining of explosives|
|US6153252||19. Apr. 1999||28. Nov. 2000||Ethicon, Inc.||Process for coating stents|
|US6159951||2. Dez. 1997||12. Dez. 2000||Ribozyme Pharmaceuticals Inc.||2'-O-amino-containing nucleoside analogs and polynucleotides|
|US6160084||23. Febr. 1999||12. Dez. 2000||Massachusetts Institute Of Technology||Biodegradable shape memory polymers|
|US6165212||28. Juni 1999||26. Dez. 2000||Corvita Corporation||Expandable supportive endoluminal grafts|
|US6165486||19. Nov. 1998||26. Dez. 2000||Carnegie Mellon University||Biocompatible compositions and methods of using same|
|US6166130||30. Apr. 1999||26. Dez. 2000||Cohesion Technologies, Inc.||Method of using crosslinked polymer compositions in tissue treatment applications|
|US6169170||3. Sept. 1997||2. Jan. 2001||Lynx Therapeutics, Inc.||Oligonucleotide N3′→N5′Phosphoramidate Duplexes|
|US6171609||23. Okt. 1995||9. Jan. 2001||Neorx Corporation||Therapeutic inhibitor of vascular smooth muscle cells|
|US6174330||1. Aug. 1997||16. Jan. 2001||Schneider (Usa) Inc||Bioabsorbable marker having radiopaque constituents|
|US6177523||14. Juli 1999||23. Jan. 2001||Cardiotech International, Inc.||Functionalized polyurethanes|
|US6183505||11. März 1999||6. Febr. 2001||Medtronic Ave, Inc.||Method of stent retention to a delivery catheter balloon-braided retainers|
|US6187045||10. Febr. 1999||13. Febr. 2001||Thomas K. Fehring||Enhanced biocompatible implants and alloys|
|US6210715||31. März 1998||3. Apr. 2001||Cap Biotechnology, Inc.||Calcium phosphate microcarriers and microspheres|
|US6224626||1. Apr. 1999||1. Mai 2001||Md3, Inc.||Ultra-thin expandable stent|
|US6228845||21. Okt. 1998||8. Mai 2001||Medtronic, Inc.||Therapeutic intraluminal stents|
|US6240616||15. Apr. 1997||5. Juni 2001||Advanced Cardiovascular Systems, Inc.||Method of manufacturing a medicated porous metal prosthesis|
|US6245076||22. Mai 2000||12. Juni 2001||Advanced Cardiovascular Systems, Inc.||Temperature activated adhesive for releasably attaching stents to balloons|
|US6245103||1. Aug. 1997||12. Juni 2001||Schneider (Usa) Inc||Bioabsorbable self-expanding stent|
|US6248344||15. Apr. 1998||19. Juni 2001||Heimo Ylänen||Composite and its use|
|US6251135||8. März 1999||26. Juni 2001||Schneider (Usa) Inc||Radiopaque marker system and method of use|
|US6251142||9. Dez. 1997||26. Juni 2001||Sorin Biomedica Cardio S.P.A.||Implantation device and a kit including the device|
|US6273913||16. Apr. 1998||14. Aug. 2001||Cordis Corporation||Modified stent useful for delivery of drugs along stent strut|
|US6281262||12. Nov. 1998||28. Aug. 2001||Takiron Co., Ltd.||Shape-memory, biodegradable and absorbable material|
|US6284333||25. Febr. 1999||4. Sept. 2001||Scimed Life Systems, Inc.||Medical devices made from polymer blends containing low melting temperature liquid crystal polymers|
|US6287332||25. Juni 1999||11. Sept. 2001||Biotronik Mess- Und Therapiegeraete Gmbh & Co. Ingenieurbuero Berlin||Implantable, bioresorbable vessel wall support, in particular coronary stent|
|US6290721||21. Okt. 1997||18. Sept. 2001||Boston Scientific Corporation||Tubular medical endoprostheses|
|US6293966||20. Apr. 1998||25. Sept. 2001||Cook Incorporated||Surgical stent featuring radiopaque markers|
|US6303901||21. Apr. 2000||16. Okt. 2001||The Regents Of The University Of California||Method to reduce damage to backing plate|
|US6312459||30. Juni 1999||6. Nov. 2001||Advanced Cardiovascular Systems, Inc.||Stent design for use in small vessels|
|US6327772||13. Apr. 1999||11. Dez. 2001||Medtronic, Inc.||Method for fabricating a planar eversible lattice which forms a stent when everted|
|US6375826||14. Febr. 2000||23. Apr. 2002||Advanced Cardiovascular Systems, Inc.||Electro-polishing fixture and electrolyte solution for polishing stents and method|
|US6379381||3. Sept. 1999||30. Apr. 2002||Advanced Cardiovascular Systems, Inc.||Porous prosthesis and a method of depositing substances into the pores|
|US6387121||8. Aug. 2000||14. Mai 2002||Inflow Dynamics Inc.||Vascular and endoluminal stents with improved coatings|
|US6388043||23. Febr. 1999||14. Mai 2002||Mnemoscience Gmbh||Shape memory polymers|
|US6395326||31. Mai 2000||28. Mai 2002||Advanced Cardiovascular Systems, Inc.||Apparatus and method for depositing a coating onto a surface of a prosthesis|
|US6409761||20. Apr. 2001||25. Juni 2002||G. David Jang||Intravascular stent|
|US6423092||20. Aug. 2001||23. Juli 2002||Ethicon, Inc.||Biodegradable stent|
|US6461632||18. Apr. 2001||8. Okt. 2002||Synthes (U.S.A.)||Hardenable ceramic hydraulic cement|
|US6464720||30. März 2001||15. Okt. 2002||Cook Incorporated||Radially expandable stent|
|US6479565||16. Aug. 1999||12. Nov. 2002||Harold R. Stanley||Bioactive ceramic cement|
|US6485512||27. Sept. 2000||26. Nov. 2002||Advanced Cardiovascular Systems, Inc.||Two-stage light curable stent and delivery system|
|US6492615||12. Okt. 2000||10. Dez. 2002||Scimed Life Systems, Inc.||Laser polishing of medical devices|
|US6494908||22. Dez. 1999||17. Dez. 2002||Ethicon, Inc.||Removable stent for body lumens|
|US6495156||11. Mai 2001||17. Dez. 2002||Merck Patent Gmbh||Biocements having improved compressive strength|
|US6511748||6. Jan. 1999||28. Jan. 2003||Aderans Research Institute, Inc.||Bioabsorbable fibers and reinforced composites produced therefrom|
|US6517888||28. Nov. 2000||11. Febr. 2003||Scimed Life Systems, Inc.||Method for manufacturing a medical device having a coated portion by laser ablation|
|US6527801||13. Apr. 2000||4. März 2003||Advanced Cardiovascular Systems, Inc.||Biodegradable drug delivery material for stent|
|US6537589||25. Juli 2000||25. März 2003||Kyung Won Medical Co., Ltd.||Calcium phosphate artificial bone as osteoconductive and biodegradable bone substitute material|
|US6539607||13. Sept. 2000||1. Apr. 2003||University Of North Carolina At Charlotte||Enhanced biocompatible implants and alloys|
|US6540777||15. Febr. 2001||1. Apr. 2003||Scimed Life Systems, Inc.||Locking stent|
|US6554854||10. Dez. 1999||29. Apr. 2003||Scimed Life Systems, Inc.||Process for laser joining dissimilar metals and endoluminal stent with radiopaque marker produced thereby|
|US6565599||28. Dez. 2000||20. Mai 2003||Advanced Cardiovascular Systems, Inc.||Hybrid stent|
|US6569191||27. Juli 2000||27. Mai 2003||Bionx Implants, Inc.||Self-expanding stent with enhanced radial expansion and shape memory|
|US6569193||22. Juli 1999||27. Mai 2003||Advanced Cardiovascular Systems, Inc.||Tapered self-expanding stent|
|US6572672||17. Mai 2002||3. Juni 2003||Nanoproducts Corporation||Nanotechnology for biomedical products|
|US6574851||31. Juli 2000||10. Juni 2003||Advanced Cardiovascular Systems, Inc.||Stent made by rotational molding or centrifugal casting and method for making the same|
|US6585755||29. Juni 2001||1. Juli 2003||Advanced Cardiovascular||Polymeric stent suitable for imaging by MRI and fluoroscopy|
|US6592614||1. Dez. 2000||15. Juli 2003||Medtronic Ave, Inc.||Cuffed endoluminal prosthesis|
|US6592617||16. Jan. 2001||15. Juli 2003||Boston Scientific Scimed, Inc.||Three-dimensional braided covered stent|
|US6613072||18. Juli 1997||2. Sept. 2003||Gore Enterprise Holdings, Inc.||Procedures for introducing stents and stent-grafts|
|US6626939||18. Dez. 1997||30. Sept. 2003||Boston Scientific Scimed, Inc.||Stent-graft with bioabsorbable structural support|
|US6635269||24. Nov. 1998||21. Okt. 2003||Morphoplant Gmbh||Immobilizing mediator molecules via anchor molecules on metallic implant materials containing oxide layer|
|US6645243||8. Jan. 1998||11. Nov. 2003||Sorin Biomedica Cardio S.P.A.||Stent for angioplasty and a production process therefor|
|US6656162||9. Dez. 2002||2. Dez. 2003||Microchips, Inc.||Implantable drug delivery stents|
|US6664335||30. Nov. 2000||16. Dez. 2003||Cardiac Pacemakers, Inc.||Polyurethane elastomer article with “shape memory” and medical devices therefrom|
|US6666214||28. Sept. 2001||23. Dez. 2003||Psimedica Limited||Biomaterial|
|US6667049||28. März 2001||23. Dez. 2003||Ethicon, Inc.||Relic process for producing bioresorbable ceramic tissue scaffolds|
|US6669723||22. Nov. 2002||30. Dez. 2003||Scimed Life Systems, Inc.||Stent having variable properties and method of its use|
|US6676697||17. März 1998||13. Jan. 2004||Medinol Ltd.||Stent with variable features to optimize support and method of making such stent|
|US6679980||13. Juni 2001||20. Jan. 2004||Advanced Cardiovascular Systems, Inc.||Apparatus for electropolishing a stent|
|US6689375||14. Okt. 2002||10. Febr. 2004||Coripharm Medizinprodukte Gmbh & Co. Kg||Resorbable bone implant material and method for producing the same|
|US6695920||27. Juni 2001||24. Febr. 2004||Advanced Cardiovascular Systems, Inc.||Mandrel for supporting a stent and a method of using the mandrel to coat a stent|
|US6706273||14. Aug. 2000||16. März 2004||Ivoclar Vivadent Ag||Composition for implantation into the human and animal body|
|US6709379||2. Nov. 1999||23. März 2004||Alcove Surfaces Gmbh||Implant with cavities containing therapeutic agents|
|US6719934||25. Apr. 2001||13. Apr. 2004||Boston Scientific Scimed, Inc.||Process for making bioabsorbable self-expanding stent|
|US6719989||8. Sept. 2000||13. Apr. 2004||Pentax Corporation||Sustained release drug carrier, and method of manufacturing sustained release drug carrier|
|US6720402||8. Mai 2002||13. Apr. 2004||Mnemoscience Gmbh||Shape memory polymers|
|US6746773||25. Sept. 2001||8. Juni 2004||Ethicon, Inc.||Coatings for medical devices|
|US6752826||14. Dez. 2001||22. Juni 2004||Thoratec Corporation||Layered stent-graft and methods of making the same|
|US6753007||1. Nov. 2001||22. Juni 2004||Wright Medical Technology, Inc.||Controlled release composite|
|US6764505||12. Apr. 2001||20. Juli 2004||Advanced Cardiovascular Systems, Inc.||Variable surface area stent|
|US6818063||24. Sept. 2002||16. Nov. 2004||Advanced Cardiovascular Systems, Inc.||Stent mandrel fixture and method for minimizing coating defects|
|US6846323||15. Mai 2003||25. Jan. 2005||Advanced Cardiovascular Systems, Inc.||Intravascular stent|
|US6894145||16. Juni 2003||17. Mai 2005||Organic Vision Inc.||Methods to purify polymers|
|US6992127||25. Nov. 2002||31. Jan. 2006||Ast Products, Inc.||Polymeric coatings containing a pH buffer agent|
|US20010044652||14. Juni 2001||22. Nov. 2001||Moore Brian Edward||Stents with multi-layered struts|
|US20020002399||8. Mai 2001||3. Jan. 2002||Huxel Shawn Thayer||Removable stent for body lumens|
|US20020004060||17. Juli 1998||10. Jan. 2002||Bernd Heublein||Metallic implant which is degradable in vivo|
|US20020004101||30. Aug. 2001||10. Jan. 2002||Schneider (Usa) Inc.||Drug coating with topcoat|
|US20020062148||26. Febr. 1997||23. Mai 2002||Charles C. Hart||Kinetic stent|
|US20020065553||3. Dez. 2001||30. Mai 2002||Scimed Life System, Inc.||Method for manufacturing a medical device having a coated portion by laser ablation|
|US20020103526||13. Dez. 2001||1. Aug. 2002||Tom Steinke||Protective coating for stent|
|US20020111590||25. Sept. 2001||15. Aug. 2002||Davila Luis A.||Medical devices, drug coatings and methods for maintaining the drug coatings thereon|
|US20020116050||26. Febr. 2002||22. Aug. 2002||Scimed Life Systems, Inc.||Stents with temporary retaining bands|
|US20020138133||20. Mai 2002||26. Sept. 2002||Scimed Life Systems, Inc.||Stent with variable properties|
|US20020155144||20. Apr. 2001||24. Okt. 2002||Tomasz Troczynski||Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation|
|US20020161114||22. Jan. 2002||31. Okt. 2002||Gunatillake Pathiraja A.||Shape memory polyurethane or polyurethane-urea polymers|
|US20030033001||27. Apr. 2001||13. Febr. 2003||Keiji Igaki||Stent holding member and stent feeding system|
|US20030065355||27. Sept. 2002||3. Apr. 2003||Jan Weber||Medical devices comprising nonomaterials and therapeutic methods utilizing the same|
|US20030093107||27. Sept. 2002||15. Mai 2003||Edward Parsonage||Medical devices comprising nanocomposites|
|US20030100865||9. Dez. 2002||29. Mai 2003||Santini John T.||Implantable drug delivery stents|
|US20030105518||10. Jan. 2003||5. Juni 2003||Debashis Dutta||Biodegradable drug delivery material for stent|
|US20030105530||4. Dez. 2001||5. Juni 2003||Inion Ltd.||Biodegradable implant and method for manufacturing one|
|US20030134099||27. Jan. 2003||17. Juli 2003||Bioamide, Inc.||Bioabsorbable fibers and reinforced composites produced therefrom|
|US20030171053||10. Dez. 2002||11. Sept. 2003||University Of Washington||Medical devices comprising small fiber biomaterials, and methods of use|
|US20030187495||1. Apr. 2002||2. Okt. 2003||Cully Edward H.||Endoluminal devices, embolic filters, methods of manufacture and use|
|US20030208259||26. Juni 2001||6. Nov. 2003||Pentech Medical Devices Ltd.||Polymeric stents and other surgical articles|
|US20030209835||28. März 2003||13. Nov. 2003||Iksoo Chun||Method of forming a tubular membrane on a structural frame|
|US20030226833||12. Mai 2003||11. Dez. 2003||Scimed Life Systems, Inc.||Laser cutting of stents and other medical devices|
|US20030236563||20. Juni 2002||25. Dez. 2003||Dan Fifer||Stent delivery catheter with retention bands|
|US20040071781||19. Mai 2003||15. Apr. 2004||Ferro Corporation||Composite particles and method for preparing|
|US20040093077||6. Aug. 2003||13. Mai 2004||Jason White||Stent with micro-latching hinge joints|
|US20040098095||30. Sept. 2003||20. Mai 2004||Burnside Diane K.||Stent-graft with bioabsorbable structural support|
|US20040111149||6. Aug. 2003||10. Juni 2004||Stinson Jonathan S.||Bioabsorbable marker having radiopaque constituents|
|US20040127970||30. Dez. 2002||1. Juli 2004||Saunders Richard J.||Polymer link hybrid stent|
|US20040143317||17. Jan. 2003||22. Juli 2004||Stinson Jonathan S.||Medical devices|
|US20040167610||26. Febr. 2003||26. Aug. 2004||Fleming James A.||Locking stent|
|US20050181015||12. Febr. 2004||18. Aug. 2005||Sheng-Ping (Samuel) Zhong||Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles|
|US20050209680||28. Juni 2004||22. Sept. 2005||Gale David C||Polymer and metal composite implantable medical devices|
|US20050278929||16. Juni 2004||22. Dez. 2005||National Taipei University Technology||Process of manufacturing stent with therapeutic function in the human body|
|US20060199876||4. März 2005||7. Sept. 2006||The University Of British Columbia||Bioceramic composite coatings and process for making same|
|US20060264531||9. Febr. 2006||23. Nov. 2006||Zhao Jonathon Z||Biodegradable medical devices with enhanced mechanical strength and pharmacological functions|
|US20070026069||26. März 2004||1. Febr. 2007||Shastri Venkatram P||Biommetic hierarchies using functionalized nanoparticles as building blocks|
|DE4407079B4||3. März 1994||18. Jan. 2007||Boston Scientific Ltd., St. Michael||Intraluminal-Aufspannvorrichtung und Transplantat|
|DE19731021A1||18. Juli 1997||21. Jan. 1999||Meyer Joerg||In vivo abbaubares metallisches Implantat|
|DE19856983A1||10. Dez. 1998||30. Dez. 1999||Biotronik Mess & Therapieg||Implantierbare, bioresorbierbare Gefäßwandstütze, insbesondere Koronarstent|
|EP0108171B1||22. Okt. 1982||4. Mai 1988||Meadox Medicals, Inc.||Synthetic woven double-velour graft|
|EP0144534A3||16. Aug. 1984||17. Dez. 1986||Allied Corporation||Prosthetic devices|
|EP0364787B1||29. Sept. 1989||4. März 1992||EXPANDABLE GRAFTS PARTNERSHIP a Texas General Partnership||Expandable intraluminal graft|
|EP0397500B1||10. Mai 1990||2. Aug. 1995||United States Surgical Corporation||Synthetic semiabsorbable yarn, fabric and tubular prosthesis|
|EP0464755B1||1. Juli 1991||3. Mai 1995||Nissho Corporation||Artificial tubular organ|
|EP0493788B1||23. Dez. 1991||25. Sept. 1996||MUDR. MILAN KRAJICEK CSc.||Three-layer vascular prosthesis|
|EP0554082B1||28. Jan. 1993||29. Dez. 1997||Advanced Cardiovascular Systems, Inc.||Expandable stent|
|EP0578998B1||22. Juni 1993||8. Okt. 1997||Strecker, Ernst Peter, Dr.-med.Prof.||Implantable percutaneous endoprosthesis|
|EP0604022A1||24. Nov. 1993||29. Juni 1994||Advanced Cardiovascular Systems, Inc.||Multilayered biodegradable stent and method for its manufacture|
|EP0621017A1||25. Apr. 1994||26. Okt. 1994||Advanced Cardiovascular Systems, Inc.||Ratcheting stent|
|EP0623354B1||20. Apr. 1994||2. Okt. 2002||Medtronic, Inc.||Intravascular stents|
|EP0665023B1||13. Juli 1994||21. Apr. 2004||Otsuka Pharmaceutical Co., Ltd.||Medical material and process for producing the same|
|EP0709068A3||27. Okt. 1995||4. Juni 1997||Medinol Ltd||X-ray visible stent|
|EP0970711B1||29. Juni 1999||13. Okt. 2004||Ethicon, Inc.||Process for coating stents|
|EP1600178B1||27. Mai 2005||7. Apr. 2010||Cordis Corporation||Biodegradable vascular device with buffering agent|
|GB2247696B||Titel nicht verfügbar|
|1||Anonymous, Bioabsorbable stent mounted on a catheter having optical coherence tomography capabilities, Research Disclosure, Sep. 2004, pp. 1159-1162.|
|2||Ansari, End-to-end tubal anastomosis using an absorbable stent, Fertility and Sterility, vol. 32(2), pp. 197-201 (Aug. 1979).|
|3||Ansari, Tubal Reanastomosis Using Absorbable Stent, International Journal of Fertility, vol. 23(4), pp. 242-243 (1978).|
|4||Bull, Parylene Coating for Medical Applications, Medical Product Manufacturing News 18, 1 pg. (Mar. 1993).|
|5||Casper et al., Fiber-Reinforced Absorbable Composite for Orthopedic Surgery, Polymeric Materials Science and Engineering, vol. 53 pp. 497-501 (1985).|
|6||Chen et al., Toughening of Polypropylene-Ethylene Copolymer with Nanosized CaCo3 and Styrene-Butadiene-Styrene, J. of Applied Polymer Science, vol. 94, (2004), pp. 796-802.|
|7||Detweiler et al., Gastrointestinal Sutureless Anastomosis Using Fibrin Glue: Reinforcement of the Sliding Absorbable Intraluminal Nontoxic Stent and Development of a Stent Placement Device, Journal of Investigative Surgery, vol. 9(2), pp. 111-130 (Mar./Apr. 1996).|
|8||Detweiler et al., Sliding, Absorbable, Reinforced Ring and an Axially Driven Stent Placement Device for Sutureless Fibrin Glue Gastrointestinal Anastomisis, Journal of Investigative Surgery, vol. 9(6), pp. 495-504 (Nov./Dec. 1996).|
|9||Detweiler et al., Sutureless Anastomosis of the Small Intestine and the Colon in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue, Journal of Investigative Surgery, vol. 8(2), pp. 129-140 (Mar. 1995).|
|10||Detweiler et al., Sutureless Cholecystojejunostomy in Pigs Using an Absorbable Intraluminal Stent and Fibrin Glue, Journal of Investigative Surgery, vol. 9(1), pp. 13-26 (Jan./Feb. 1996).|
|11||Devanathan et al., Polymeric Conformal Coatings for Implantable Electronic Devices, IEEE Transactions on Biomedical Engineering, vol. BME-27(11), pp. 671-675 (1980).|
|12||Elbert et al., Conjugate Addition Reactions Combined with Free-Radical Cross-Linking for the Design of Materials for Tissue Engineering, Biomacromolecules, vol. 2, pp. 430-441 (2001).|
|13||Hahn et al., Biocompatibility of Glow-Discharge-Polymerized Films and Vacuum-Deposited Parylene, J Applied Polymer Sci, vol. 38, pp. 55-64 (1984).|
|14||Hahn et al., Glow Discharge Polymers as Coatings for Implanted Devices, ISA, pp. 109-111 (1981).|
|15||He et al., Assessment of Tissue Blood Flow Following Small Artery Welding with an Intraluminal Dissolvable Stent, Microsurgery, vol. 19(3), pp. 148-152 (1999).|
|16||International Search Report for PCT/US2007/020021, mailed Feb. 12, 2009, 7 pgs.|
|17||Invitation to Pay Additional Fees for PCT/US2007/009757, filed Apr. 19, 2007, mailed Nov. 13, 2007, 8 pgs.|
|18||Kelley et al., Totally Resorbable High-Strength Composite Material, Advances in Biomedical Polymers, vol. 35, pp. 75-85 (1987).|
|19||Kikuchi et al., "Development of guided bone regeneration membrane composed of beta-tricalcium phosphate and poly (L-lactide-co-glycolide-co-epsilon-caprolactone) composites", Biomaterials 25, pp. 5979-5986 (2004).|
|20||Kikuchi et al., "Development of guided bone regeneration membrane composed of β-tricalcium phosphate and poly (L-lactide-co-glycolide-co-ε-caprolactone) composites", Biomaterials 25, pp. 5979-5986 (2004).|
|21||Kubies et al., Microdomain Structure In polylactide-block-poly(ethylene oxide) copolymer films, Biomaterials, vol. 21, pp. 529-536 (2000).|
|22||Kutryk et al., Coronary Stenting: Current Perspectives, a companion to the Handbook of Coronary Stents, pp. 1-16 (1999).|
|23||Martin et al., Enhancing the biological activity of immobilized osteopontin using a type-1 collagen affinity coating, J. Biomed. Mater. Res., vol. 70A, pp. 10-19 (2004).|
|24||Mauduit et al., Hydrolytic degradation of films prepared from blends of high and low molecular weight poly(DL-lactic acid)s, J. Biomed. Mater. Res., vol. 30, pp. 201-207 (1996).|
|25||Middleton et al., Synthetic biodegradable polymers as orthopedic devices, Biomaterials, vol. 21, pp. 2335-2346 (2000).|
|26||Muller et al., Advances in Coronary Angioplasty: Endovascular Stents, Coron. Arter. Dis., vol. 1(4), pp. 438-448 (Jul./Aug. 1990).|
|27||Nichols et al., Electrical Insulation of Implantable Devices by Composite Polymer Coatings, ISA Transactions, vol. 26(4), pp. 15-18 (1987).|
|28||Nielsen et al., 2nd Ed., Mechanical Properties of polymers and composites, (1993), pp. 384-385.|
|29||Peuster et al., A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits, Heart, vol. 86, pp. 563-569 (2001).|
|30||Pietrzak et al., Bioabsorbable Fixation Devices: Status for the Craniomaxillofacial Surgeon, J. Craniofaxial Surg., vol. 2, pp. 92-96 (1997).|
|31||Pietrzak et al., Bioresorbable implants-practical considerations, Bone, vol. 19, No. 1, Supplement Jul. 1996, pp. 109S-119S.|
|32||Pietrzak et al., Bioresorbable implants—practical considerations, Bone, vol. 19, No. 1, Supplement Jul. 1996, pp. 109S-119S.|
|33||Redman, Clinical Experience with Vasovasostomy Utilizing Absorbable Intravasal Stent, Urology, vol. 20(1), pp. 59-61 (Jul. 1982).|
|34||Rust et al., The Effect of Absorbable Stenting on Postoperative Stenosis of the Surgically Enlarged Maxillary Sinus Ostia in a Rabbit Animal Model, Archives of Otolaryngology, vol. 122(12) pp. 1395-1397 (Dec. 1996).|
|35||Schatz, A View of Vascular Stents, Circulation, vol. 79(2), pp. 445-457 (Feb. 1989).|
|36||Schmidt et al., Long-Term Implants of Parylene-C Coated Microelectrodes, Med & Biol Eng & Comp, vol. 26(1), pp. 96-101 (Jan. 1988).|
|37||Spagnuolo et al., Gas 1 is induced by VE-cadherin and vascular endothelial growth factor and inhibits endothelial cell apoptosis, Blood, vol. 103, pp. 3005-3012 (2004).|
|38||Tamai et al., Initial and 6-Month Results of Biodegradable Poly-l-Lactic Acid Coronary Stents in Humans, Circulation, pp. 399-404 (Jul. 25, 2000).|
|39||Thamaraiseivi et al., Biological Evaluation of Bioceramic Materials, Trends Biomater. Artif. Organs, vol. 18(1), pp. 9-14 (2004).|
|40||Tollon, "Fabrication of Coated Biodegradable Polymer Scaffolds and their Effects of Murine Embryonic Stem Cells," pp. 1-62 (2005).|
|41||Tsuji et al., Biodegradable Polymeric Stents, Current Interventional Cardiology Reports, vol. 3, pp. 10-17 (2001).|
|42||U.S. Appl. No. 10/317,435, filed Dec. 11, 2002, Hossainy et al.|
|43||Van Der Meer et al., The influence of basic filler materials on the degradation of amorphous D- and L-lactide copolymer, Univ. of Leiden, The Netherlands, (1996), pp. 359-361.|
|44||Van Der Meer et al., The influence of basic filler materials on the degradation of amorphous D- and L-lactide copolymer, Univ. of Leiden, The Netherlands, (1996), pp. 359-361.|
|45||Völkel et al., Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105), Biochimica et Biophysica Acta 1663, pp. 158-166 (2004).|
|46||Völkel et al., Targeting of immunoliposomes to endothelial cells using a single—chain Fv fragment directed against human endoglin (CD105), Biochimica et Biophysica Acta 1663, pp. 158-166 (2004).|
|47||von Recum et al., Degradation of polydispersed poly(L-lactic acid) to modulate lactic acid release, Biomaterials, vol. 16, pp. 441-445 (1995).|
|48||Yau et al., Modern Size-Exclusion Liquid Chromatography, Wiley-Interscience Publication, IX-XV (1979).|
|49||Zhang et al., Processing and properties of porous poly(L-lactide) bioactive glass composites, Biomaterials 25, (2004), pp. 2489-2500.|
|Zitiert von Patent||Eingetragen||Veröffentlichungsdatum||Antragsteller||Titel|
|US8309114||5. Mai 2011||13. Nov. 2012||Advanced Cardiovascular Systems, Inc.||Method of making Polymer-bioceramic composite implantable medical devices|
|US8512735||16. Okt. 2012||20. Aug. 2013||Abbott Cardiovascular Systems Inc.||Method of making polymer-bioceramic composite implantable medical devices|
|US8685432||23. März 2009||1. Apr. 2014||University Of Utah Research Foundation||Controlled release tissue graft combination biomaterials|
|US9199004 *||1. Juli 2013||1. Dez. 2015||Abbott Cardiovascular Systems Inc.||Polymer-bioceramic composite implantable medical device with different types of bioceramic particles|
|US20090324683 *||31. Dez. 2009||Evans Bruce G||Controlled release tissue graft combination biomaterials|
|US20110207843 *||25. Aug. 2011||Advanced Cardiovascular Systems, Inc.||Polymer-Bioceramic Composite Implantable Medical Devices|
|US20140018907 *||1. Juli 2013||16. Jan. 2014||Abbott Cardiovascular Systems Inc.||Polymer-bioceramic composite implantable medical device with different types of bioceramic particles|
|US-Klassifikation||424/423, 977/931, 424/489, 977/776, 977/753|
|Internationale Klassifikation||A61K9/14, A61F2/86|
|Unternehmensklassifikation||Y10S977/753, Y10S977/776, A61L31/148, B29C47/0023, B29C47/0021, B29C47/0014, A61F2/82, A61L31/128, Y10S977/831, Y10S977/931, B29C47/0007, A61L31/127|
|Europäische Klassifikation||A61L31/14K, A61L31/12D6, A61L31/12D4|
|31. Aug. 2006||AS||Assignment|
Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GALE, DAVID C.;WANG, YUNBING;HOSSAINY, SYED FAIYAZ AHMED;AND OTHERS;REEL/FRAME:018225/0133;SIGNING DATES FROM 20060710 TO 20060809
Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GALE, DAVID C.;WANG, YUNBING;HOSSAINY, SYED FAIYAZ AHMED;AND OTHERS;SIGNING DATES FROM 20060710 TO 20060809;REEL/FRAME:018225/0133
|24. Nov. 2014||FPAY||Fee payment|
Year of fee payment: 4